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Hepatitis C virus (HCV) infection is the leading cause of cirrhosis, hepatocellular
carcinoma, and liver transplantation. Current treatment rates and efficacy are
inadequate to manage the disease burden caused by HCV; thus, efforts are needed
to control HCV transmission. Besides the well-known transmission routes, which are
health-care-associated transmission and transmission through injecting drugs, HCV
could also be transmitted by sexual contact, especially among men having sex with
men (MSM). MSM also have higher drug use prevalence than the general
population, which may contribute to HCV infection by sexual disinhibition and other
risky behavior. Since 2000, there have been emerging reports indicating HCV
epidemics or outbreaks among HIV positive MSM in Europe, Australia and North
America. However, previous studies often focused on HIV positive and/or injection
drug using MSM, and there is still a need for study targeting on non-injection drug
using MSM. The overall objective of this study is to investigate characteristics
associated with HCV infection in MSM who used drugs but not injected drugs (NIDU
MSM).

This study used data from two projects, DASH project and YMAP project, and
applied latent class analysis and dyadic data analysis to analyze the data. The main
finding of this study included: (1) overall HCV prevalence in NIDU MSM was higher
than the rest of general population; (2) NIDU MSM >=42 years old had a higher risk
of HCV infection than NIDU MSM <42 years old; (3) NIDU MSM >=42 years old who
used >6 drugs were associated with increased probability of HCV infection among all
NIDU MSM; (4) among NIDU YMSM, syphilis mono-infection, HIV mono-infection,
and syphilis/HIV co-infection were associated with increased risk of HCV infection.

This study may provide a better understanding of HCV transmission among NIDU
MSM. These results may provide a profile of subgroups with a higher HCV
transmission possibility among NIDU MSM. In the long term, the results of the study
may guide the development of healthcare and behavioral intervention programs
related to HCV transmission, and may also guide tailored screening or treatment
strategies for HCV infection.
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BACKGROUND
Background and literature Review
Hepatitis C Virus infection
Hepatitis C virus (HCV) infection affects primarily the liver and causes acute and chronic
hepatitis in humans with a high propensity for chronicity. [1] It has become a leading
cause of cirrhosis, hepatocellular carcinoma, and liver transplantation. [2]
Worldwide, three to four million people are newly infected each year and 170 million
people are chronically infected accounting for 3% of the global population. [3] In the
United States, it is estimated that 3.5 million people are living with HCV infection, which
accounts for about 1% of the population. [4] The number of estimated new annual HCV
infections increased from 16,500 in 2011 to 41,200 in 2016 [5], tripling in six years.
Young people ages 20-29 years who inject drugs account for the greatest increases,
and the highest overall number of cases. [5]
Among infected individuals, about 25% could spontaneously eliminate the virus, and the
remaining 75% are chronically infected. Of those with chronic HCV infection, the risk of
cirrhosis of the liver is between 15–30% within 20 years. [6] Worldwide, about 399,000
people die each year due to all HCV-related causes, mainly from HCV-related cirrhosis
and hepatocellular carcinoma. [7]
The current treatment paradigm can achieve 95% cure rates. [8] However, these
medicines are very expensive in many high- and middle-income countries, which
creates a major barrier for people with HCV infection to obtain access to proper
treatment. Meanwhile, the rate of access to diagnosis and treatment is low. In 2015, of
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the people living with HCV globally, 20% knew their diagnosis, and only 7.4% of those
diagnosed were started on treatment in 2015 [7]. A study modeling current and future
disease burden of HCV indicates that the current treatment rate and efficacy are
inadequate to reduce the disease burden of HCV; thus, more efforts are needed to
control HCV transmission. [9]
HCV can be transmitted from one individual to another through bodily fluids. The
first transmission route has proven to be health-care-associated transmission, such as
unsafe injection practices and procedures. [10] Approximately half of the chronic
infection happened through this transmission route in developing countries. [9] The
second transmission route is well considered to be transmission among people who
inject drugs through unsterile injection equipment and contaminated drug solutions.
According to a systematic review, this route primary contributed to the infection,
especially incident infection, in middle- and high-income countries [11]. The third
transmission route could be sexual transmission. Since 2000, there has been increasing
reports of HCV epidemic among HIV positive MSM in Northern Europe, North America,
and Australia [12-15], linked to high-risk sex behaviors and potentially underreported
non-injection drug use [16, 17].
HCV among people who use drugs
There is a high prevalence of illicit drug use in the United States and the prevalence has
been increasing in recent decades. Approximately 29.5 million aged 12 years or older
(0.6% of the population) are suffering from drug use disorders [18]. In 2014, in North
America, the drug-related death rate is 164.5 /per million among 15-64 years, 3.5 times
than the global average number.
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Among people who use drugs, about one third are injection drug users (IDU) [19]
constituting the “core” population of HCV infection. Among IDU 40%-90% are infected
by HCV, and IDU accounted for more than 50% of all cases of HCV. [20] For noninjection drug users (NIDU), less attention was paid to their HCV infection. One
systematic review, however, reported that the HCV prevalence ranged from 2.3% to
35.3% in NIDU and is much higher than the prevalence in the non-drug using
population. [21]
HCV among MSM
There are an estimated 8.4 million MSM in the US [22], of whom 16% are infected with
HIV [23]. During the last decade, there have been increasing reports of acute HCV
epidemic among MSM in Western countries. [13, 14, 24-26] One recently published
systematic review and meta-analysis, which quantitatively synthesized 28 studies since
2000, reported that the pooled estimated incidence rate was 6.4 per 1000 person-year
(95%CI: 5.0-7.5), and the incident rate of HCV among HIV positive MSM was 19 times
than that of HCV among HIV negative MSM. [27] Another recently published systematic
review and meta-analysis, which quantitatively synthesized 42 studies from 1990 to
2015, studied HCV prevalence among HIV positive MSM and reported that the pooled
hepatitis C virus prevalence was 8.1%. [28]
It is believed that HCV was first introduced in this population by parenteral transmission
through injection drug use [14, 29, 30], then researchers proved HCV transmission
network among MSM by using phylogenetic approaches [17] and sexual transmission
was thought to be the most possible transmission mechanism [12].
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In this population, researchers revealed that the HCV epidemics have been associated
with behavioral factors (such as group sex, recreational drug use, sex with drug use,
sex practices disrupting the anal mucosal), and biological characteristics (such as HIV
co-infection, and recent history of syphilis). [27, 31]
HCV among MSM who use drugs
Research suggests that MSM are more likely to use drugs compared to adults in the
general population. According to a National Household Survey on Drug Abuse, the
prevalence of drug use in the past month is 16.3% among MSM, while 9.9% among
men only having female partners. [32] A national MSM sample found a 42% previous
year prevalence for any non-injection substance use. [33] This higher rate of drug use
can be a reaction to homophobia, discrimination, or violence that MSM experience
because of their sexuality. [34] One systematic review and meta-analysis, targeted only
HIV positive MSM, reported that the pooled HCV prevalence was 40% among IDU and
was 6.7% among NIDU, and the prevalence was increasing over time among both
subgroups. [28]
Summarizing various studies, there are three distinct characteristics of drug use
behavior among MSM. First, most drug use MSM are not drug-dependent, but rather
use episodically (i.e., using substances less than weekly). National HIV Behavioral
Surveillance (NHBS) data show that 69%–86% of drug use MSM report less than
weekly substance use [32–35]. This pattern perhaps less concerning from a drugdependence perspective, however, is associated with high-risk sexual behaviors [24,
38]. Second, drug use MSM are more likely to use drugs related to sex (meth, EDDs,
poppers), or club drugs (Ketamine, MDMA, GHB, etc.), which are related to high-risk
7

sexual behaviors and contribute substantially to HIV transmission rates. Third, multiple
drug use (i.e. taking more than one substance at the same time or periodically over a
period of time) is very common among drug using MSM. For example, in the San
Francisco NHBS sample, more than 90% of Methamphetamine, cocaine or popper
using MSM reported using other substances. In a sample of MSM from San Diego, who
were HIV positive and used methamphetamine, 95% used multiple drugs. Two studies
in New York targeting club drug using MSM, reported similar findings. Among various
drug using MSM samples, 11%-44% of respondents reported recent use of more than
three substances.
It is biologically plausible that mucosally administered drug use may directly be
associated with HCV infection by sharing insertion equipment, mucosal trauma and
mucosal hyperemia. [35] Drug using may also alter mental status, decrease pain,
improve sexual function or desire, therefore drug-using MSM may get involved in riskier
sexual behaviors, such as multiple sex partners, marathon sex, anonymous sex, low
condom use, and other risk behaviors, such as exchange sex for drugs and money, and
sharing needles when injecting drugs. Those risk behaviors substantially contribute to
the transmission of HIV, Hepatitis, and other STDs. However, it is difficult to disentangle
the extent to which non-injecting drug use directly facilitates HCV infection versus the
effect of disinhibiting riskier sexual behaviors.
There are case-control studies of HIV positive MSM from UK and German, showing
higher levels of nasally administrated drug use in HCV cases than in controls. [15, 36]
One study in the US indicated that methamphetamine use during sex was the most
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significant risk factor for HCV transmission in non-injection drug use, HIV-positive MSM.
[37]
There is a need for more understanding the practice associated with HCV infection in
NIDU MSM, which could lead to better informed and more effective prevention. This
proposed study intended to use traditional epidemiology method and latent class
analysis to explore risk factors associated with HCV infection in NIDU MSM, and to use
a social network analysis approach to evaluate risk factors associated with HCV
infection in NIDU MSM.
Latent class analysis
Latent class analysis (LCA) is a statistical model, in which several items are used to
determine the class of individuals. [38, 39] The hypothesis of LCA is the similarity of the
response for the individuals within a class. [40] LCA assumes homogeneity within a
class, heterogeneity among classes, and that the difference in response to items within
a class is only due to random error. [39, 40] Different from cluster analysis, which is not
a statistical model, LCA can provide not only the results of classification but also the
probability that one individual belongs to a certain class. In addition, LCA can provide
the probability that one individual belongs to a certain class given a “yes” response to a
certain item.
People who use drugs often use different kinds of drugs, by multiple routes of
administrations (for example smoking, chewing, swallowing, snorting, inhaling or taking
in pill form ), and patterns of substance use vary among different populations [41]. Drugusing MSM are also not a homogeneous population. Only focusing on certain kinds of

9

drugs may result in lack of generalizability. LCA is a well-established methodology to
identify subgroups with distinct behavior in a population. This technique has been
applied to explore classes of drug use [42-48] and then to explore associations of each
class with specific risk factors.
Researchers using LCA analysis among MSM who use drugs have focused primarily on
HIV infection and related risk factors. In these studies, classes of MSM who use drugs
are between 2 to 6, such as low-risk (limited or negligible) drug use, recreational/club
drug use, conventional drug use, street drug use, multiple drug use, etc. In one US
internet-based MSM sample, a using sex-drugs group was more likely to engage in
particular potentially high-risk sexual behaviors, and a distinct polydrug use group was
identified. [49] Another US internet-based MSM sample showed that MSM who used
polydrug were more likely to report unprotected anal intercourse, and sexual transmitted
infection. [50] One US internet-based African American MSM sample identified 3
classes: persons who used polydrug were more likely to report sex exchange, recent
sexually transmitted infection compared to other classes, and persons who used alcohol
and polydrug were more likely to report sex under the influence [51]. A young MSM
sample from Chicago reporting high substance use rates were classified into 3 distinct
groups (persons who used alcohol and marijuana, polydrug, and less marijuana) [52]. In
a Malaysia Asia internet-based MSM sample, an ATS (amphetamine-type stimulant)
class was more likely to have more than 6 male sex partners, have group sex, report
inconsistent condom use, be HIV infected, and have a sexually transmitted infection
compared to a low-risk drug use group [53]. Very few published literatures can be
found, which applied LCA for classifying NIUD MSM and explored the association with
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HCV infection and other risk factors. This study used LCA to identify subgroups of NIDU
MSM and evaluate the relationship between drug use patterns and HCV infection.
Social network analysis
The science and techniques of network analysis have a great impact on the research on
the dynamics of interacting elements. [54] The concept of “social network” was first
introduced by J.A. Barnes in 1954 in the context of anthropology, representing social
contact between individuals. [55] In 1985, this concept was first applied in Epidemiology
on an HIV study to show the usefulness of a network approach to evaluate an infectious
agent with unknown etiology and to develop strategies to reduce the transmission
through personal contact. [56]
The spread of an infectious disease naturally forms a transmission network, and this
network underlies the person to person contact network. Especially for sexually
transmitted disease, people are usually infected by their close network, not by a random
person at large. By observing and analyzing the structure of contact network, we may
get an insight into the epidemiological dynamics (understand and predict the spread of
infection), and the knowledge of transmission route defined by network structure can be
used as part of intervention and prevention.
Social network models incorporate both individual attributes (socioeconomic status,
age, race, weight, etc) and relationship between elements (kinship, friendship, sexual
relationship, affiliated organizations, etc.), which may lead to or influence the infection of
disease, whereas traditional infectious disease models are only based on individual
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attributes and uniform-mixing assumption (assume the probability of person-to-person
contacts are the same for each individual).
Inspired by the first application of social network analysis on HIV/AIDS [56], more
research has been conducted in the field of STDs by using sexual network or social
network information, such as HIV [57-61], syphilis [62-64], gonorrhea [65], and
chlamydia [66]. Very few published studies have used a social network approach to
study sexually transmitted HCV. One study incorporated epidemiological and
phylogeographical approaches indicating that some subtype of HCV was associated
with younger people, possibly with higher rates of sexual transmission, suggesting
social factors may play a key role in determining the rate and pattern of HCV
transmission. [67] However, further study is needed in this field to further understand
sexual transmission by using social network approach.
This study explored HCV transmission factors by using a simple network structure -dyads within egocentric networks. This study analyzed the relationships between the
character of dyadic links in a subset of egocentric networks of MSM and the likelihood
that subjects are infected with HCV. According to Neaigus, dyads data may also yield
useful results and is feasible among hidden populations such as MSM [68].
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Knowledge gap
Very few published studies have examined HCV infection among NIDU MSM, which
could be a neglected subpopulation at risk of HCV infection. In addition, research on
sexual transmission of HCV among heterosexual and homosexual couples has yielded
mixed results. This proposed study would infer, although cannot confirm, sexual
transmission evidence among the study populations. Furthermore, latent class analysis
and social network analysis methods have been used for HIV related study among
MSM, but seldom used for HCV study among MSM. This proposed study is attempting
to use these approaches to evaluate and discuss HCV infection by using the subset of
data from two NIH funded projects: Drugs, AIDS, STDs, and Hepatitis project (DASH,
PI: Lu-Yu Hwang), and Young Men’s Affiliation Project (YMAP, PI: Kayo Fujimoto).

Public Health Significance
This study may provide a better understanding of HCV transmission among NIDU MSM.
We will obtain the characteristics of the study populations associated with HCV
infection. These results may provide a profile of subgroups with a higher HCV
transmission possibility among NIDU MSM. In the long term, the results of the proposed
study may guide the development of healthcare and behavior intervention programs
related to HCV transmission, and may also guide tailored screening or treatment
strategy on HCV infection. Therefore, the results of the study may help to reduce the
subsequent burden of advanced liver diseases attributed to HCV in NIDU MSM, by
slowing the incidence and decreasing the prevalence of HCV infection in this
marginalized and underrepresented population.
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Specific Aims and Hypothesis
This proposed study will explore the risk factors of HCV infection in two study
populations of NIDU MSM. The results will provide a profile of sub-population in MSM
that susceptible to HCV infection, and provide some evidence of sexual transmission of
HCV among NIDU MSM.
Specific aim 1
To determine risk factors associated with HCV infection among NIDU MSM in Houston,
using a subset of data from Drugs, AIDS, STDs, and Hepatitis (DASH) project.
Hypothesis: NIDU MSM who engage in risky sexual behaviors (unprotected anal
intercourse, multiple sexual partners, trading sex, etc.) will be more likely to have HCV
infection, compared to those who do not engage in these risk sexual behaviors.
Specific aim 2
To investigate subgroups of non-injection drug use among MSM using latent class
analysis, and to evaluate the effect of these subgroups on HCV infection, using a subset
of data from Drugs, AIDS, STDs, and Hepatitis (DASH) project.
Hypothesis: NIDU MSM have distinct drug use subgroups, and these subgroups are
different in the risk of HCV infection. Sex-related drug use will be associated with HCV
infection.
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Specific aim 3
To examine relationships between dyadic links in a subset of egocentric networks of
NIDU MSM, engagement in high-risk sex behaviors, and the likelihood that subjects are
infected with HCV, using a subset of data from Young Men’s Affiliation Project (YMAP).
Hypothesis: dyadic links and ego attributes related to high-risk sex behaviors, HIV
infection and syphilis infection will be associated with HCV infection among young NIDU
MSM.
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PARENT STUDY: DASH PROJECT
The data of the first and second studies came from the data of Drugs, AIDS, STDs, and
Hepatitis (DASH) project.
The DASH project was a community-based intervention study among non-treatment
drug using population for HIV, HBV, and HCV prevention. The project screened 2800
individuals who injection and non-injection drugs from February 2004 to October 2007 in
two inner city neighborhood communities in Houston, Texas. Participants were recruited
by using outreach and chain referral method. [20] Chain referral method is a sampling
technique where a small pool of initial study subjects is used to recruit future subjects
through their social networks. This sampling method is often used to reach hidden
populations. This study was approved by the Committee for the Protection of Human
Subjects at the University of Texas Health Science Center.
The eligibility criteria for individuals included in the screening process were: 1) 18 years
old or above, 2) self-reported living in Houston, 3) self-reported use of illegal and nonmedical prescribed drugs including cocaine or heroin in the last 48 hours and confirmed
presence of drug metabolites by urinalysis (OnTrak Varian Testik, Palo Alto, CA.), 4)
willing to sign the informed consent form for HIV, HBV, and HCV testing. Individuals
with negative drug metabolites test were excluded from the study.
Data collection
Every individual completed an initial screening interview, which comprised a verbally
administered questionnaire via computer-assisted personal interview (CAPI, QDS,
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Bethesda, MD) to obtain the demographic information, history of drug use for drugs,
sexual behaviors, history of sexually transmitted diseases, and blood transfusion and
occupational exposure to blood.
Separate from the screening interview, the baseline enrollment interview collected
additional information on drug use, including frequency of drug use in past 30 days, a
detailed history of binging for each of these drugs, experience in injection drug use.
Laboratory methods
All serum specimens obtained from screened individuals were tested for HIV1/2
antibodies, HBsAg and HCV antibody infection using Core Combo HIV-HBsAg-HCV
(Core Diagnostics, United Kingdom). Verification of HIV was conducted by enzyme
immunoassay (EIA), using Abbott PPC Commander system, third generation HIV
antibody test (Abbott Laboratories, Chicago, IL). Verification of HCV, anti-HBs, and antiHBc was conducted by Abbott AxSYM system, using microparticle enzyme
immunoassay (MEIA) (Abbott Laboratories, Chicago, IL).
Definition of HCV infection was the presence of antibody to HCV. HIV infection was
defined as repeatedly reactive results by EIA. Case definition of HBV was the detection
of anti-HBs or anti-HBc.
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PARENT STUDY: YMAP PROJECT
The material of the third study obtained from Young Men’s Affiliation Project (YMAP) in
Houston, TX.
YMAP is a longitudinal network study conducted from 2014 to 2017 to investigate social
networks and attendance history at social venues and health-promoting venues among
young MSM, and to determine how these networks affect HIV and sexually transmitted
disease risk and prevention in Houston, TX and Chicago, IL. [62, 70-72] Respondents
were included in this study if they identified as male sex assigned at birth and current
male identification, were aged between 16-29 years old, reported oral or anal sex with
another male in the past 12 months, were residing in and planning to remain in Houston
for the following year, and were English-speaking. The study was approved by the
institutional review boards at each location (HSC-SPH-12-0830).
Data collection
The sampling method in the YMAP study was Respondent Driven Sampling (RDS). [73]
This method has been applied to recruit hard-to-reach populations such as MSM. The
“seeds” were defined as respondents enrolled via representatives at health service
providing facilities or at social venues. “Sprouts” were defined as respondents who were
referred by “seeds”. Four vouchers were given to each participant to recruit other YMSM
(sprouts) to produce chained samples.
Interviews were conducted using a computer-based personal-interview combined with a
computer-assisted self-interview delivered via Qualtrics (Qualtrics LLC, Provo, Utah). In
the computer-assisted personal interviews, the trained data collector read questions
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from the computer and entered data. Information were collected on demographic
characteristics, drug use, social and sexual networks, and behavior with peers, and
participants’ affiliation with community organizations and businesses.
Laboratory methods
After the interview, each participant provided biological blood specimen for HIV, HCV,
and syphilis. HIV tests included fourth generation rapid test, using Alere Determine HIV1/2 Ab/Ag combo (Abbott Laboratories, Chicago, IL), viral load quantitative test, using
Cobas AmpliPrep/Cobas TaqMan HIV-1 test kit, version 2,0 (Roche Molecular
Diagnostics, Pleasanton, CA), and confirmatory test, using Geenius HIV -1/2
Confirmatory test (Bio-rad, Marnes-la-Coquette, France). Tests for syphilis infection
included rapid plasma regain (RPR) test, using Macro-Vue RPR Card test Kit (BD
Diagnositics, Franklin Lakes, NJ), and fluorescent treponemal antibody FTA test, using
Immunofluorence Assay FTA-Absorption Test System (Zeus Scientific, Branchburg,
NJ). The test for HCV was HCV antibody rapid test (Boson Biotech, Xiamen, CN).
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METHODS FOR SPECIFIC AIM 1
Study design and study population
This study was a cross-sectional study using a subset of screening data from DASH
project, restricting to individuals who reported never having injected drugs and ever
having male-to-male sex. Among 2800 individuals who were screened, 273 NIDU MSM
were selected in this proposed study (Figure 1).

Screened in DASH
N=2800

IDU

NIDU

N=961

N=1839

NIDU

NIDU MSM

Not MSM

N=273

N=1566

Figure 1. Study population for specific aim 1
Ascertainment of dependent and independent variables
Dependent variable was HCV status, which is defined as the existence of HCV antibody
or not. Independent variables were demographic measures such as age, race, living
arrangement, jail history of more than 24 hours, and behavior measures such as
number of sexual partners, frequency of condom use, trade sex for money or drugs,
drug or alcohol use in past 7 days, number of drugs used in past 7 days, and biological
measures such as HIV status, HBV status, history of sexually transmitted diseases.
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Power estimation
Assuming a sample size of 284 participants and a two-sided test with 0.05 significant
level, a minimal odds ratio was 1.7 to obtain a power of at least 80%, for overall HCV
prevalence is 15.5% and assuming 5%-15% in unexposed group and 10%-30% in
exposed group (Table 1). This power estimation was calculated by using OpenEpi
software. [69]
Table 1 Study power (1-𝛽) estimation given sample size of 273, significant level of 0.05
and different HCV prevalence in exposed/unexposed groups for specific aim 1

Statistical analysis
Univariable analysis was conducted for each demographic characteristic, behavioral
and biological variable. Number and percentage were calculated for categorical
variables, while median and interquartile range (IQR) was computed for continuous
variables. Then, Exact Logistic Regression was conducted for bivariable analysis to
statistically test the association between the independent variables and HCV infections,
and crude odds ratio (cOR) and 95% confidence interval with p-values were obtained. A
final multivariable model was constructed by first using all variables significant at p<0.25
in bivariable analysis as full model, then backward elimination was used to reach the
final model. The statistical significance level was 5%. SAS 9.4 was used to manage and
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analyze the data (Cary, NC). Hosmer-Lemeshow goodness of fit test was used to test
the fit of the final model.
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METHODS FOR SPECIFIC AIM 2
Study design and study population
This study was a cross-sectional study using a subset of baseline data from the DASH
project, restricted to participants who reported male-to-male sex and never injected
drugs. Among 2800 individuals who were screened, 1260 who were negative for HIV
and HBV were enrolled for intervention to improve HBV vaccination adherence, and
within the enrolled participants, 118 NIDU MSM were selected in this proposed study.
(Figure 2)
Screened
N=2800

Not enrolled
HIV (+) or HBV (+)
N=1540

Enrolled
N=1260

IDU
N=410

NIDU
N=850

Not MSM
N=732

MSM
N=118

Figure 2. Study population for specific aim 2
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Measures
For latent class analysis, indicators used for class identification included the use of the
following drugs: crack cocaine, powder cocaine, methamphetamine, marijuana, alcohol,
and heroin.
For multi-nominal logistic regression, the dependent variable was the class of persons
who used drugs classified by latent class analysis (e.g. class 1 vs 2, class 2 vs 3 and
class 1 vs 3) (see statistical analysis below). The independent variable comprised
demographic measures (such as age, race/ethnicity, education level, living
arrangement, jail history of more than 24 hours), risk behavior variables (such as
number of sexual partners in the past 30 days, sexual orientation, condom use, trading
sex for money or drugs in past 30 days), HCV status, sexually transmitted diseases
histories.
For multivariable logistic regression, the dependent variable was HCV status.
Independent variables were demographic measures (such as age, race/ethnicity,
education level, living arrangement, hail history of more than 24 hours), risk behavior
variables (such as number of sexual partners in the past 30 days, sexual orientation,
condom use, trading sex for money or drugs in past 30 days), sexually transmitted
diseases history, and classes of drug use (drug use subgroups defined by latent class
analysis).
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Power estimation
For latent class analysis no formal approach has been taken so far; however, several
useful statistics were used to evaluate the fitting of the model.
For logistic regression, assuming a sample size of 110 participants and a two-sided test
with 0.05 significant level, a minimal detectable odds ratio was 3.8 to obtain a power of
at least 80%, for overall HCV prevalence is 17% and assuming 5%-15% in unexposed
group and 20%-35% in exposed group (Table 2). This power estimation was calculated
by using OpenEpi software. [69]
Table 2 Study power (1-𝛽) estimation given sample size of 118, significant level of 0.05
and different HCV prevalence in exposed/unexposed groups for specific aim 2.

Statistical analysis
Descriptive statistics was used to demonstrate the characteristics of the study sample.
Latent class analysis was used to examine the subgroups of drug use (Figure 3). Drug
use indicator variables were used in the LCA model. Starting with a one class model
and increasing the number of classes, a series maxima were reached. Multiple model fit
statistics were used to determine the best-fitting, most parsimonious model, including
the chi-square value, Bayesian information criteria (BIC), LMR and so on.
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*Crack Powder
MarijuMeth
alcohol Heroin
Cocaine cocaine
ana

Covariate predictors:
Demographics
Sex Behaviors
STDs
HCV

other

Drug use
latent
classes

Figure 3. Latent class model of drug use among MSM with covariate predictors.

Figure 3. Latent class model of drug use among MSM with covariate predictors

* For each drug use, the indicator variable will include two variables:
1) The frequency of drug use in the past 30 days:
* The use,
reply for the question: “Have you ever uesd this drug?”
0=never
1=ever use but not used in the past 30 days,
2=less than 5 times,
After deciding on3=5-29
the appropriate
number of classes that best fit the data, multi-nominal
times,
4=30 times or more.
logistic regression
was used
touse
explore
the characteristics of drug use subgroups and
2) The duration
of drug
(in years).

the association between classes (different subgroups of drug use) and demographical,
behavioral, HCV status variables. A final multivariable model was constructed by first
using all variables significant at p<0.25 in bivariable analysis as full model, then
backward elimination was used to reach the final model. In addition, multivariable
logistic regression was used to examine characteristics of individual associated with
HCV infection, controlling for drug use subgroups. A final multivariable model was
constructed by first using all variables significant at p<0.25 in bivariable analysis as full
model, then backward elimination was used to reach the final model.
The statistical significance level was 5%. Mplus 6.1 (Muthén & Muthén, CA) was used
to conduct the LCA model building. SAS 9.4 (Cary, NC) was used to manage the data
and build multi-nominal and multivariable logistic regression.
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METHODS FOR SPECIFIC AIM 3
Study design and study population
This study was a cross-sectional network study. The study sample was a subset of
YMAP baseline data restricted to participants who report never having injected drugs,
collected from December 2014 to December 2015 in Houston. A total of 366
participants in YMAP were selected into this study.
YMAP HOUSTON
YMSM
N=378

Never used drugs

DU MSM

n=5

n=369

Drug use info is
missing
n=4

NIDU

IDU

n=366

n=3

Figure 4. Study population for specific aim 3

Measures
Dependent variable was HCV status, which was defined as the existence of HCV
antibody or not.
Independent variables included two sets, respondent’s measures and sexual network
dyad measures. For respondent’s measures, demographic information (such as age,
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race, education level, living arrangement, and jail history for more than 24 hours) was
used. For sexual network dyad measures, all these data were treated as clustered data
on respondent, including sexual ties (determined by asking respondents to nominate up
to five people with whom they had sex within the past six months), and their behavioral
measures (such as main/casual relationship, frequency of condom use, whether used
drugs before sex, HIV status of both respondent and sex partner, and syphilis status of
both respondent and sex partner).
Statistical analysis
The unit of analysis was the dyad, which was the pair of respondent and his nominated
sexual partner.
Chi-square test was used to assess the relationship between baseline respondents' and
their sexual partners’ characteristics, such as age, race/ethnicity, sexual orientation, and
HIV status.
Homophily was defined of the following variable, age homophily (evaluated by the
absolute value of age difference between a respondent and his nominated sex partner),
race/ethnicity homophily (evaluated by dichotomy scale: same/discordant), HIV
serostatus homophily (evaluated as 1= respondent HIV seropositivity and respondent’s
perception about sex partner’s positivity, 2=respondent HIV seropositive and
respondent’s perception about sex partner negative, 3=respondent HIV seropositivity
and respondent’s perception about sex partner’s unknown, 4=respondent HIV
seronegative and respondent’s perception about sex partner positive, 5=respondent HIV
seronegative and respondent’s perception about sex partner negative, 6=respondent
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HIV seronegative and respondent’s perception about sex partner unknown).
Generalized Estimating Equations model (GEE) model, which can justify cluster
observation of respondents [74] was used to conduct bivariate and multivariable
analysis. Bivariate analyses were conducted between HCV status and each
independent variable using crude odds ratio (cOR) and 95% confidence intervals.
Multivariable GEE model was conducted to statistically test if there is an association
between HCV infection status and the dyadic network measures. The statistical
significance level was 5%. SAS 9.4 (Cary, NC) was used to manage the data and
conduct the GEE analysis.

30

JOURNAL ARTICLE
Article I: Hepatitis C infection and its associated risk factors in men who have sex
with men who reported non-injection use of drugs
This article has been formatted for the Journal of Viral Hepatitis

ABSTRACT
Background: Hepatitis C virus infection is more prevalent among high risk populations
in the U.S. We assessed risk factors for HCV infection among men who have sex with
men (MSM) who acknowledged drug use but not injection drug use. Methods: The
DASH project, a community-based study in Houston, Texas, collected data from people
who reported injection or non-injection use of drugs (drug use was defined as selfreported use of marijuana, alcohol, methamphetamines, cocaine, heroin, uppers,
downers in the past 7 days and confirmed by urine test) collected in 2004-2007. Our
analysis focused on the MSM who reported drug use but no injection drug use. Exact
logistic regression was used to determine demographic characteristics, sexual risk
behaviors and sexually transmitted disease history associated with HCV infection.
Results: Among 273 MSM, the HCV prevalence was 14.7%. Only age was significantly
associated with HCV infection. Compared to participants aged 19-41, those aged 42-74
had 2.1 times the odds of having HCV infection (95%CI: 1.4-3.0). HIV status and sexual
risk behaviors such as unprotected intercourse, multiple sex partners, and trading sex
for money or drugs were not significantly associated with increased HCV infection.
Conclusion: MSM ages 42 years old and above were at greater risk for HCV infection
than other age groups among MSM who reported drug use but no injection drug use.
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Sexual risk behaviors were not identified as a risk factor of HCV infection. We call for
health education about HCV infection to increase awareness of HCV testing and
treatment in this subpopulation of MSM who reported drug use but no injection drug
use.
INTRODUCTION
Hepatitis C virus (HCV) infection affects primarily the liver and causes acute and chronic
hepatitis with a high propensity for chronicity[1]. It is the leading cause of cirrhosis,
hepatocellular carcinoma, and liver transplantation in the United States[2]. In the United
States, it is estimated that 3.5 million people are living with HCV infection, which
accounts for about 1% of the population[3]. Studies shows the HCV prevalence is
higher in some risk populations such as people who use drugs [4, 5] and HIV-positive
men who have sex with men (MSM) [6]. HCV prevalence among IDU is reported as
70% and among NIDU 17.9%. [7] HCV prevalence among IDU is reported as 70% and
among NIDU 17.9%. [7] However, the rate of access to diagnosis and treatment is low;
of the people living with HCV globally, 20% knew their diagnosis, and only 7.4% of the
diagnosed were started on treatment [8]. In addition, current treatment rates and
efficacy are inadequate to manage the disease burden caused by HCV [9]; thus, efforts
are needed to reduce HCV transmission.
Besides health-care-associated transmission and transmission through injecting drugs,
other transmission routes, such as sexual transmission, sharing equipment of noninjection drug use, are not conclusive. HCV was found to be transmitted by sexual
contact, especially among HIV-positive MSM [10-14], but for HIV-negative MSM, sexual
contact might not increase the risk of HCV infection [15, 16]. Transmission by sharing
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drug use equipment for non-injection drug use has also been reported but with mixed
results [17-22]. One systematic review, however, reported that the HCV prevalence
ranged from 2.3% to 35.3% in the population who reported drug use but no injection
drug use and was higher than the prevalence in the population who did not use
drugs[5].
For MSM and drug-using behavior, MSM were found to have a higher drug use
prevalence than in the general population [23, 24], which might contribute to HCV
infection by sexual disinhibition and other risky behaviors. One systematic review and
meta-analysis, which targeted only HIV-positive MSM, reported that the pooled HCV
prevalence was 6.7% among NIDU, and the prevalence was increasing over time [6].
Previous studies on risk factors associated with HCV infection focused mainly on HIVpositive MSM and/or MSM who reported injection drug use, so studies are needed that
target MSM who reported drug use but no injection drug use. This study estimated HCV
prevalence and examined risk factors associated with HCV infection among MSM who
reported drug use but no injection drug use in Houston, TX. The hypothesis of this study
was that sexual risk behaviors were significantly associated with HCV infection in MSM
who reported drug use but no injection drug use. These results may provide a profile of
subgroups with a higher HCV transmission possibility among MSM who reported drug
use but no injection drug use. In the long term, the results of the study may guide the
development of healthcare and behavior intervention programs related to HCV infection,
providing better informed and more effective HCV prevention.
METHODS
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Study set and participant sampling
Data were obtained from the Drugs, AIDS, STDs and Hepatitis (DASH) project, which
was a community-based intervention study for HIV, HBV, and HCV prevention among a
drug-using population [25]. The project screened 2,800 individuals with injection and
non-injection use of drugs from February 2004 to October 2007 in two inner-city
neighborhood communities in Houston, TX. Participants were recruited by using
outreach and chain referral method. The eligibility criteria included in the screening
process were: (1) 18 years old or above; (2) self-reported living in Houston; (3) selfreported use of illegal and non-medical prescribed drugs, including cocaine or heroin in
the last 48 hours and confirmed presence of drug metabolites by urinalysis (OnTrak
Varian Testik, Palo Alto, CA.); (4) willingness to sign the informed consent form for HIV,
HBV, and HCV testing.
Data collection
Every individual completed an initial screening interview, which constituted a verbally
administered questionnaire via computer-assisted personal interview (CAPI, QDS,
Bethesda, MD) to obtain socio-demographic information (such as age, gender,
race/ethnicity, sexual orientation, living arrangement, and jail history of more than 24
hours); history of drug use for drugs including marijuana, alcohol, methamphetamine,
heroin, cocaine, uppers and downers (such as types and frequency of drugs used in the
past 48 hours and 7 days, and lifetime injection drug use); sexual behaviors (such as
number of sexual partners in the past 30 days, frequency of condom use, and trading
sex for money or drugs in past 30 days); history of sexually transmitted diseases (such
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as gonorrhea, herpes, chlamydia, and trichomoniasis); blood transfusion and
occupational exposure to blood.
All serum specimens obtained from screened individuals were tested for HIV1/2
antibodies, HBsAg and HCV antibody infection using Core Combo HIV-HBsAg-HCV
(Core Diagnostics, United Kingdom). Verification of HIV was conducted by enzyme
immunoassay (EIA), using Abbott PPC Commander system, third generation HIV
antibody test (Abbott Laboratories, Chicago, IL). Verification of HCV, anti-HBs, and antiHBc was conducted by Abbott AxSYM system, using microparticle enzyme
immunoassay (MEIA) (Abbott Laboratories, Chicago, IL).
Definition of HCV infection was the presence of antibody to HCV. HIV infection was
defined as repeatedly reactive results by EIA. Case definition of HBV was the detection
of anti-HBs or HBsAg or anti-HBc.
Statistical analysis
Univariable analyses were conducted for each socio-demographic characteristic, sexual
risk behavioral and biological variable. Numbers and percentages were calculated for
categorical variables, while medians and interquartile ranges (IQR) were computed for
continuous variables. Chi-square or Fisher exact tests were used to test the difference
of HCV status among different categories of each independent variable. Then, exact
logistic regression analyses were performed for bivariable analysis to statistically test
the association between each independent variable and HCV status, and odds ratio
(cOR) and 95% confidence interval with p-values were obtained. Interaction terms were
evaluated in the model. The statistical significance level was set at 5%. Hosmer-
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Lemeshow goodness of fit test was used to test the fit of the final model. SAS 9.4 was
used to manage and analyze the data (Cary, NC).
RESULTS
There were 273 MSM who reported drug use but no injection drug use in this study; of
these, 14.7% were infected with HCV (Table 1). Age of the sample ranged from 19 to 74
years old, with the mean age of 39.6 years old (IQR: 35-46), 85% were African
American, 61% were homeless at least once, 25% were currently living on the street,
and 66% reported their sexual orientation as bisexual. About one third of the
participants had traded sex for money, half had traded sex for drugs, and one third
never used condoms while having sex. A total of 77% had been in jail, 49% had been
diagnosed with a sexual transmitted disease, and 19% were HIV positive. The majority
of the study participants had used crack cocaine (98%), alcohol (83%) and marijuana
(58%) in the last 7 days. The demographic, socio-behavioral, and 7-day drug use
profiles stratified by HCV status are presented in table 1.
Of the demographic, socio-behavioral, and drug use variables, only age was observed
to have significant association with HCV status. Compared to the 19-41 year age group
(HCV prevalence 7.1%), and the 42-74 year age group (24.6%) had more than 2 times
the odds of having HCV infection (OR = 2.1, 95%CI: 1.4-3.0) (Table 2).
Being Caucasian, currently homeless, of straight sexual orientation, having a blood
transfusion history, occupational blood exposure history, or being HIV positive was
associated with increased HCV infection, but none of these associations were
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statistically significant at the 5% level. No significant difference in HCV infection was
discovered in any kind of drug use in the last 7 days.
Interaction terms were examined in the multivariable model, but none of them were
significant at the 5% level. Only age was retained in the multivariable logistic regression
model after backward selection. Also, the association between age and HCV infection
did not change more than or equal to 15% when any other variables were entered in the
model. The final model included only age as a predictor of HCV infection.
DISCUSSION
We found that the overall HCV prevalence in MSM who reported drug use but no
injection drug use was relatively high, and only age was significantly associated with
HCV infection, specifically among MSM ages 42 years old and above, who had the
highest risk of HCV infection compared with the younger age group. In addition, sexual
risk behavior and HIV infection were not significantly associated with HCV infection.
Overall, the HCV prevalence was 14.7% in these MSM who reported drug use but no
injection drug use. The result was comparable to an average of 14.0% HCV infection in
the general population who reported non-injection drug use, reported in a systematic
review of 28 studies [5], but higher than the HCV prevalence in the general MSM
population (2.8%), reported in a large community-based study in New York [27]. The
prevalence was also higher than that among HIV-positive MSM (8.1%), described in a
systematic review and meta-analysis of 42 studies [28]. These comparisons may
suggest that, although it could not be explicitly determined, the behavior of non-injection
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drug use outweighed the behavior of MSM with regard to HCV infection among these
MSM who reported drug use but no injection drug use.
Age was the only factor that was significantly associated with HCV infection. Among
MSM ages 45 years and older, the HCV prevalence was 27%, 8 times more likely to
have HCV infection than the youngest age group (19-35 years old). This result was
consistent with previous studies which demonstrated people born during 1945-1965,
known as baby boomers, had the highest possibility of HCV infection compared with
other generations [29]. Moreover, the baby boomers in our study had much higher HCV
prevalence than general baby boomers, whose HCV prevalence was estimated to be
3.3% [30], indicating a high HCV disease burden in the subpopulation of the baby
boomer generation who are MSM and report drug use but no injection drug use.
For the possible transmission route of HCV, our study findings did not support our
hypothesis that sexual risk behaviors, including unprotected intercourse, multiple sex
partners, and trading sex for money or drugs, significantly increased the risk of HCV
infection. This result was consistent with that Joy et al. [31] who suggest the reuse of
glass and metal syringes in medical practice dating back to 1940 to 1960 was
associated with the highest expansion of HCV infection in the generation of baby
boomer. Importantly, Joy et al. used molecular-clock approaches and reconstructed the
epidemiology of HCV in North America, destigmatizing the baby boomers with
nosocomial activity as the main contributor to HCV epidemic in North America, rather
than risky sex and injection drug use behavior [31].
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It is worth noting that HIV infection did not significantly increase the risk of HCV
infection, which contrasts with the increasing reports of an HCV epidemic or outbreak in
HIV-positive MSM in Europe, Australia, and North America since 2000 [10-14]. The
possible reason was that the HCV infection rate was also high in HIV-negative
participants in the present study, which raised the bar that detected the effect of HIV coinfection on promoting HCV transmission in this study. Another possible reason was
that the HIV and HCV epidemics have unrelated transmission dynamics in this
population, which was also reported in one study in Hong Kong [32]. To confirm the
transmission dynamics, investigation of social and sexual networks combined with
phylogenetic approaches may help unveil the transmission pattern of the two viruses.
Regarding types of drug use, none of them showed association with HCV infection. The
reason was likely that only the last 7-day drug use information was collected in this
screening investigation, which may not relate to chronic HCV infection. Information on
detailed drug use history may help explain the relationship between drug use types and
HCV infection. In addition, increased risk of HCV infection related to sharing implements
for smoking or snorting drugs, as well as sharing non-injection drugs, should be
evaluated, although some studies show no association between sharing implements or
non-injection drugs with HCV infection [17-20], other studies have reported opposite
results [21, 22].
Strengths of the study, besides the relatively large sample size, include that HCV and
HIV status were confirmed by laboratory test in this project, not self-report, which greatly
reduced misclassification. In addition, the use of drugs was confirmed by urine test, not
self-report, which reduced information bias. However, there were several limitations in
39

this study. First, information collected in these screening data did not include some
specific kinds of drug preferred by MSM in recent years, for example, sex/club drugs
(ketamine, MDMA, LSD, and erectile dysfunction drugs). In addition, several sexual risk
behaviors specific to MSM were not examined, such as frequency of receptive anal
intercourse, or experience of mucosal trauma during sex. Furthermore, as mentioned
above, sharing equipment for non-injection drug use was not investigated in this study,
which might also be a transmission path of HCV infection. Last but not least, most of the
participants were African American, which limited the generalizability of the results in
this study to other racial/ethnic populations. Further study is warranted specifically
among MSM who report drug use but no injection drug use, with greater racial/ethnic
diversity, to more fully examine risk factors related to HCV infection.
In conclusion, individuals aged 45 years old and above had the highest risk of HCV
infection among MSM who reported drug use but no injection drug use; sexual risk
behaviors were not identified as a risk factor of HCV infection. For the baby boomer
generation, the HCV testing rate was very low (<14%) [33]. Two factors, non-injection
drug use and male-to-male sexual behavior, may marginalize this subpopulation in the
baby boomer generation, possibly leading to an even lower testing rate. Health
education should be promoted in this subgroup to enhance the awareness of HCV
infection and increase HCV testing rates. We also call for regulating HCV testing in
medical systems that care for this subpopulation, and for the promotion of treatment in
HCV infected individuals to attenuate the disease burden.
Funding
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Table 1 Characteristics and HCV infection among MSM who reported drug use but no
injection drug use in two inner city communities in Houston, TX (N=273)
Characteristics

Total

HCV+

HCV- Chi-square
P-value

Age (year)

<0.001

19-41

155 (56.8)

11 (7.1) 144 (92.9)

42-74

118 (43.2) 29 (24.6)

89 (75.4)

Race
Caucasian

0.478*
34 (12.5)

7 (20.6)

27 (79.4)

8 (2.9)

1 (12.5)

7 (87.5)

Hispanic
African American

231 (84.6) 32 (13.9) 199 (86.1)

Homeless

0.643

Yes

107 (39.2) 17 (15.9)

90 (84.1)

No

166 (60.8) 23 (13.9) 143 (86.1)

Homeless (currently live on street)
Yes
No

0.229
68 (24.9) 13 (19.1)

55 (80.9)

205 (75.1) 27 (13.2) 178 (86.8)

Frequency of using condom
None
Some
All

0.433
97 (35.5) 15 (15.5)

82 (84.5)

143 (52.4) 18 (12.6) 125 (87.4)
33 (12.1)

7 (21.2)

26 (78.8)

Self-considered sex orientation

0.125

Gay

49 (17.9)

3 (6.1)

46 (93.9)

Straight

44 (16.1)

9 (20.5)

35 (79.5)

Bisexual

180 (65.9) 28 (15.6) 152 (84.4)

No. of sex partners in past 4 weeks
0

0.139
57 (20.9) 11 (19.3)

46 (80.7)

1-4

109 (40.0) 19 (17.4)

90 (82.6)

>5

106 (38.8)

96 (90.6)

10 (9.4)

Trade sex for money

0.133

Yes

99 (36.3)

9 (9.1)

90 (90.9)

No

56 (20.5)

9 (16.1)

47 (83.9)

118 (43.2) 22 (18.6)

96 (81.4)

Unknown
Trade sex for drug

0.217
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Characteristics

Total

HCV+

HCV- Chi-square
P-value

Yes

137 (50.2) 15 (10.9) 122 (89.1)

No

107 (39.2) 20 (18.7)

Unknown

29 (10.6)

5 (17.2)

87 (81.3)
24 (82.8)

Blood transfusion
Yes
No

0.462*
14 (5.1)

3 (21.4)

11 (78.6)

259 (94.9) 37 (14.3) 222 (85.7)

Occupational exposure
Yes
No

0.285*
17 (6.2)

4 (23.5)

13 (76.5)

256 (93.8) 36 (14.1) 220 (85.9)

Ever in jail for 24 hours or more
Yes
No

0.973
211 (77.3) 31 (14.7) 180 (85.3)
62 (22.7)

9 (14.5)

53 (85.5)

Diagnosed sexual transmitted diseases

0.541

Yes

86 (31.5) 12 (14.0)

74 (86.0)

No

91 (33.3) 11 (12.1)

80 (87.9)

Unknown

96 (35.2) 17 (17.7)

79 (82.3)

Diagnosed syphilis ever

0.877

Yes

32 (18.1)

5 (15.6)

27 (84.4)

No

54 (30.5)

7 (13.0)

47 (87.0)

Unknown

91 (51.4) 11 (12.1)

80 (87.9)

HIV status**
Yes
No

0.565
52 (19.2)

9 (17.3)

43 (82.7)

219 (80.8) 31 (14.2) 188 (85.8)

Alcohol
Yes
No

0.614
226 (82.8) 32 (14.2) 194 (85.8)
47 (17.2)

8 (17.0)

39 (83.0)

Marijuana

0.958

Yes

158 (57.9) 23 (14.6) 135 (85.4)

No

115 (42.1) 17 (14.8)

98 (85.2)

Methamphetamines
Yes

0.594*
11 (4.0)
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1 (9.1)

10 (90.9)

Characteristics
No

Total

HCV+

HCV- Chi-square
P-value

262 (96.0) 39 (14.9) 223 (85.1)

Cocaine
Yes

0.733*
268 (98.2) 39 (14.6) 229 (85.4)

No

5 (1.8)

1 (20.0)

4 (80.0)

Heroin
Yes
No

0.182*
10 (3.7)

0 10 (100.0)

263 (96.3) 40 (15.2) 223 (84.8)

Uppers
No

NA
273 (100.0) 40 (14.7) 233 (85.3)

Downers**

0.471*

Yes
No

3 (1.1)

1 (33.3)

2 (66.7)

269 (98.5) 39 (14.5) 230 (85.5)

* Fisher exact test P-value
** Missing value: HIV status n=2, Downers n=1
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Table 2 Results of univariable exact logistic regression of factors associated with HCV
infection among MSM who reported drug use but no injection drug use in two inner-city
communities in Houston, TX (n=273)
Characteristics

OR (95% CI) P-value

Age (year)
42-74

2.1 (1.4-3.0)

19-41

Reference

<0.001

Race
Caucasian

1.4 (0.6-3.3)

0.930

Hispanic

1.5 (NA)

0.776

African American

Reference

Homeless
Yes

1.1 (0.8-1.5)

No

Reference

0.767

Homeless (currently live on street)
Yes

1.2 (0.9-1.8)

No

Reference

0.315

Frequency of using condom
None

0.9 (0.6-1.5)

1.000

Some

0.7 (0.5-1.2)

0.355

All

Reference

Self-considered sex orientation
Gay

0.4 (0.2-1.0)

0.094

Straight

1.7 (0.9-3.2)

0.215

Bisexual

Reference

No. of sex partners in past 4 weeks
1-4

1.2 (0.8-1.9)

0.649

>5

0.6 (0.4-1.0)

0.085

0

Reference

Trade sex for money
Yes

0.6 (0.4-1.0)

0.124

Unknown

1.4 (0.9-2.2)

0.280

No

Reference

Trade sex for drug
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Characteristics

OR (95% CI) P-value

Yes

0.7 (0.4-1.1)

0.238

Unknown

1.1 (0.6-2.3)

1.000

No

Reference

Blood transfusion
Yes

1.3 (0.7-2.5)

No

Reference

0.674

Occupational exposure
Yes

1.4 (0.8-2.5)

No

Reference

0.452

Ever in jail for 24 hours or more
Yes

1.0 (0.7-1.5)

No

Reference

1.000

Diagnosed sexual transmitted diseases
Yes

1.0 (0.6-1.6)

1.000

Unknown

1.3 (0.8-2.0)

0.507

No

Reference

Diagnosed syphilis ever
Yes

1.2 (0.6-2.4)

1.000

Unknown

0.9 (0.5-1.5)

0.953

No

Reference

HIV status
Yes

1.1 (0.8-1.7)

No

Reference

0.700

Alcohol
Yes

0.9 (0.6-1.4)

No

Reference

0.756

Marijuana
Yes

1.0 (0.7-1.4)

No

Reference

1.000

Methamphetamines
Yes

0.8 (0.3-2.1)

No

Reference
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1.000

Characteristics

OR (95% CI) P-value

Cocaine
Yes

0.8 (0.3-2.5)

No

Reference

1.000

Heroin
Yes

0.6 (NA)

No

Reference

0.199

Uppers
No

0.6 (NA)

0.199

Yes

1.7 (0.5-5.7)

0.761

No

Reference

Downers
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Article II: The association between non-injection drug use and hepatitis C
infection among HIV-negative men who have sex with men
This article has been formatted for the Journal of Addictive Behaviors Reports

ABSTRACT
Objectives: This study investigated the association between drug use latent class and
Hepatitis C Virus (HCV) infection in HIV-negative men who have sex with men (MSM)
who reported drug use but not injection drug use. Methods: This cross-sectional study
analyzed the data of 118 HIV-negative MSM who reported drug use but not injection
drug use recruited from two inner-city communities between 2004 and 2007. Latent
class analysis (LCA) was used to identify drug use latent classes. Multinomial logistic
regression analysis was used to evaluate the association between drug use latent class
and HCV infection. Results: Four distinct latent classes of drug use were identified: (1)
persons >=42 years old who used only crack cocaine, (2) persons about 42 years old
who used >2 drugs, (3) persons <42 years old who used >5 drugs, and (4) persons
>=42 years old who used >6 drugs. Class 4, persons >= 42 years old who used >6
drugs were significantly associated with HCV infection. Compared with persons about
42 years old who used >2 drugs, persons >=42 years old who used >6 drugs had more
than 16 times the odds of having HCV infection (adjusted OR = 16.9, 95%CI: 1.4205.4), and compared with persons <42 years old who used >5 drugs, persons >=42
years old who used >6 drugs were about 22 times as likely to have HCV infection
(adjusted OR=21.8, 95%CI: 1.5-322.8). Conclusions: The subgroup of MSM >=42
years old with non-injection but multiple use of heroin, speedball, and
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methamphetamine, in addition to crack cocaine and marijuana, had high probability of
HCV infection. Public health and education programs, as well as drug treatment and
rehabilitation programs, should be developed for this high-risk subgroup to prevent HCV
acquisition and transmission.

INTRODUCTION
Compared with the general population, men who have sex with men (MSM) are
disproportionately affected by infectious diseases, such as HIV, syphilis and other
sexually transmitted infections (STI) (CDC, 2017). MSM may also be disproportionately
affected by HCV. HCV infection, which is a leading cause of liver failure and
transplantation in the United States (Razavi et al., 2013), has been relatively
understudied in MSM until 2000, when reports of an HCV epidemic or outbreaks in
MSM began to emerge (Bottieau, Apers, Van Esbroeck, Vandenbruaene, & Florence,
2010; Giraudon et al., 2008; Urbanus, van de Laar, et al., 2009; Urbanus, van Houdt,
van de Laar, & Coutinho, 2009; van de Laar et al., 2007; Wandeler et al., 2012). Most of
these studies focused on MSM who are HIV positive, MSM who inject drugs, or both.
Studies targeting HIV-negative and non-injection drug using MSM are needed.
Although HCV prevalence rates are comparable in HIV-negative MSM and in the
general U.S. population (Blaxhult, Samuelson, Ask, & Hökeberg, 2014; Price et al.,
2013), people who use drugs but do not inject drugs have been found to have a higher
HCV infection rate (2.3% to 35.3%) than in the general population (1%) (Scheinmann et
al., 2007). Furthermore, MSM have been reported with a higher rate of drug use than in
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heterosexual men (past month prevalence 16.3% vs 9.9%) (Cochran, Ackerman, Mays,
& Ross, 2004). These results showed a higher HCV infection rate in HIV-negative MSM
with non-injection drug use than in the general population.
People who use drugs are usually heterogeneous with regard to drug types, because
drug types are various and one individual may choose multiple drug types at the same
time or different times. Analyzing types of drug use independently may overlook the
complexity of multiple drug use or result in lack of generalizability. To analyze the drug
use variables simultaneously, we applied latent class analysis to identify subgroups of
drug use (Carlson, Wang, Falck, & Siegal, 2005; Kuramoto, Bohnert, & Latkin, 2011;
Monga et al., 2007; Sherman et al., 2009; Wittchen et al., 2009), and further explored
the association between drug use subgroups and disease. In one US internet-based
MSM sample, a distinct multiple drug use group was identified (McCarty-Caplan, Jantz,
& Swartz, 2014). Another study recruited a similar sample of MSM and found that high
multiple drug using MSM were more likely to report unprotected anal intercourse, and
STIs (Yu, Wall, Chiasson, & Hirshfield, 2015). In a Malaysia Asia internet-based MSM
sample, an amphetamine-type stimulant class was associated with sexual risk behavior
and the infection of HIV and STIs, compared to a low-risk drug use group (Lim et al.,
2015).
To the best of our knowledge, there are no studies of HCV infection targeting HIVnegative MSM with non-injection drug use. To fill this knowledge gap, this study applied
LCA to identify latent classes among MSM who reported drug use not no injection drug
use, and examined the association between latent classes and HCV infection in HIVnegative MSM. It was hypothesized that, first, there are distinct latent classes in the
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target population, and, second, one or more latent classes are associated with HCV
infection. The results of this study may provide insight for HCV prevention and health
education programs targeted at HIV-negative MSM with non-injection drug use.

METHODS
Samples from DASH project
Data for the present study were collected from a cohort of people who used drugs
enrolled in the Drugs, AIDS, STDs, and Hepatitis (DASH) project, a community-based
intervention study among a non-treatment drug-using population for HIV, HBV, and
HCV prevention (Hwang et al., 2010). The DASH project recruited individuals from two
highly endemic drug-using urban neighborhoods in Houston, TX, from February 2004 to
October 2007. Participants were recruited by outreach workers using a chain referral
approach. People were eligible for the study if they were: 18 years old or above, had
local residence, self-reported use of illegal and non-medical prescribed drugs including
cocaine or heroin in the last 48 hours and confirmed presence of drug metabolites by
urinalysis (OnTrak Varian Testik, Palo Alto, CA.), and willingness to sign the informed
consent form for HIV, HBV, and HCV testing.
Individuals with negative HIV and HBV screening tests were enrolled into the baseline
study. Enrollment interviews were conducted using verbally administered questionnaires
via computer-assisted personal interview method (CAPI, QDS, Bethesda, MD). Baseline
data were from the enrollment interview. All data collection procedures and laboratory
protocols were approved by the Committee for the Protection of Human Subjects at the
University of Texas Health Science Center at Houston.
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Data for this study were restricted to 118 participants who reported male-to-male sex
and did not report any injection drug use. (See DASH study population flow chart figure
1)
Measures
For sociodemographic characteristics, information was collected on age, race/ethnicity,
sexual orientation, education level, marital status, working status, income level, living
arrangement, jail history of more than 24 hours, and drug treatment history. Sexual
behavior variables included number of male sexual partners in the past 30 days,
frequency of condom use, trading sex for money or drugs in the past 30 days, and
trading money or drugs for sex in the past 30 days. Disease status comprised selfreported STI history for gonorrhea, herpes, chlamydia, and trichomoniasis, as well as
HCV infection status, screened by HIV1/2 antibodies, HBsAg and HCV antibody Combo
test (Core Diagnostics, United Kingdom), confirmed by Microparticle enzyme
immunoassay test (Abbott Laboratories, Chicago, IL). HCV infection was defined as
HCV antibody positive. Also, history of blood transfusion, and occupational exposure to
blood was collected during the enrollment interview.
Drug use variables and age were used as latent class indicators. Drug use variables
included the participants’ response to the question, “Have you ever used the following
drugs: crack cocaine, methamphetamine, marijuana, alcohol, fry1, powder cocaine,
heroin, speedball (a mixture of heroin and cocaine) and codeine syrup?” Drug use
indicators were denoted as: “never use” (0) or “have ever used” (1). Also, age was

1

Fry: embalming fluid and phencyclidine (PCP)-laced cigarettes or marijuana sticks
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considered as an indicator variable because age has been associated with drug use
types. (Bluthenthal, Wenger, Chu, Bourgois, & Kral, 2017; Golub, Johnson, & Dunlap,
2005) Based on a median age of 42, participants were categorized as “< 42 years old”
(0) or “≥ 42 years old”.
Statistical analysis
We applied LCA to identify drug use latent classes among our MSM sample. An LCA
model uses a maximum likelihood approach to identify subgroups or classes of
individuals with similar patterns of responses to a set of indicator variables (A. L.
McCutcheon, 1987; Whitesell et al., 2006). Based on indicator variables, LCA assigns
each individual a probability of membership in the postulated multilevel latent variable
(Allan L McCutcheon, 2002). LCA assumes homogeneity within a class, heterogeneity
among classes, and that the difference in response to items within a class is only due to
random error (A. L. McCutcheon, 1987; Whitesell et al., 2006).
We started with a 1-class model and increased the number of classes through 6-class
models. To obtain the global not local maxima for each model, we used 5,000 random
starts. We used BIC (the Bayesian Information Criteria), BLRT (the parametric bootstrap
likelihood ratio test), and LMR (the Lo-Mendell-Rubin adjusted likelihood ratio test) to
select the model. In addition, we used entropy, a standardized summary measure of the
classification accuracy, to evaluate the precision of individual assignment based on their
model-based posterior probabilities. Entropy ranges from 0 to 1, and the higher entropy
value reflects the better classification (Ramaswamy, DeSarbo, Reibstein, & Robinson,
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1993). We based our final latent class solution on not only statistical significance, but
also substantive criteria, e.g., the epidemiological explanation of drug use.
After latent class identification, we conducted logistic regression models to examine the
association between class membership and HCV status, sociodemographic
characteristics, sexual behaviors, and sexual transmitted disease history. We used the
AUXILIARY (r) option (Muthñn & Muthñn, 2012) for the multinomial logistic regression
estimation. This technique incorporates the posterior-probabilities of membership into
the estimation procedure, and helps examine the fidelity and utility of the specific latent
class profiles (Petras & Masyn, 2010). We conducted bivariate associations of latent
class of drug use with each independent variable. Independent variables with a P-value
less than 0.25 were entered into the joint model, which allowed us to evaluate the
adjusted relationships between membership in a particular drug use class and HCV
infection. We used Mplus 6.1 (Muthén & Muthén, CA) to conduct the LCA model
building and multi-nominal and multivariable logistic regression and SAS 9.4 (Cary, NC)
to manage the data.
RESULTS
In the DASH parental project study, the prevalence of HCV was 36.1% among 2,800
who used drugs and were contacted for HIV/HBV/HCV screening. The predominant risk
characteristic associated with HCV infection was injection drug use (70% prevalence).
(Hwang & Grimes, 2012). Among 273 MSM who reported drug use not including
injection drug use, the HCV prevalence was 14.7%. Only age was significantly
associated with HCV infection. Compared to participants who were less than 42 years
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old, those age 42 or older had 2.1 times the odds of having HCV infection (95%CI: 1.43.0).

Among 273 MSM who reported drug use not including injection drug use, we analyzed
118 MSM who participated in the baseline interview, among whom 21 (17.8%) were
infected with HCV. Table 1 presents the sociodemographic characteristics and
behavioral variables for the analytical sample. For sociodemographic characteristics,
the age of the participants ranged from 19 to 61 years old with the mean of 39.6 years
old (IQR: 35-46), 83% were African American, 83% reported sexual orientation as
bisexual or homosexual, 76% had less than a high school education or completed high
school only, 65% were single, 50% worked less than 14 days in the past month, 50%
had an income less than 400 dollars in the past month, 46% had been homeless at
least once, 76% had been arrested and spent more than 24 hours in jail, and 35% never
received drug treatment. For sexual risk behaviors, 41% of the participants had 0 or 1
male sexual partners in the past month, about two thirds of them used condoms less
than half of the time while having sex, about two thirds of the participants had traded
sex for money or drugs in the past month, more than half had traded money for drugs or
sex in the past month. Regarding disease history, 45% had been diagnosed with STIs.
Regarding drug use behavior, the majority of participants had used multiple drugs
(defined as had ever used more than 2 drugs), and the most prevalent drug types were
crack cocaine (98%), marijuana (89%), and alcohol (86%). The prevalence of other
types of drug use were 57% for powder cocaine, 22% for codeine, 21% for fry, 14% for
methamphetamine, 6.8% for heroin, and 3.4% for speedball.
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For LCA, Table 2 presents the results of statistics and entropy for 1- through 6- latent
classes. Although the BIC value was the lowest at the 2-class model solution, LMR
supported for all 2- through 5- class model (p-value <0.05) and BLRT supported for 2through 4- class model. Entropy showed that all 3- through 6- class models had
satisfied precision (entropy >0.8). Therefore, both 3- and 4- class models were
preferable. Based on statistical significance and practical utility, we selected the 4-class
model as the best fit model.
Figure 2 shows the estimated probability of the 4-class model. Participants in class 1,
accounted for 6.5% of the sample, had high probability (>95%) of using only crack
cocaine and the lowest probability of using all other types of drugs, with 75% probability
of being 42 years old or above. We referred to class 1 as “persons >=42 years old who
used only cocaine”. Class 2 members accounted for 70.3% of the sample, had high
probability (>90%) of using crack cocaine, marijuana, and had moderate probability
(50%) of using powder cocaine, with a half of the probability of being 42 years old or
above. We referred to class 2 as “persons about 42 years old who used >2 drugs”.
Class 3 members accounted for 20.1% of the participants, had high probability (>90%)
of using crack cocaine, marijuana, powder cocaine, and especially compared with all
other classes, class 3 members had the highest probability of using fry and codeine; the
probability of being 42 years old or above was only 35%. We referred to class 3 as
“persons <42 years old who used >5 drugs”. Individuals in class 4 accounted for 3.2%
of the sample, had high probability of using all types of drugs except for fry and codeine,
specifically, the probability of using methamphetamine, heroin, and speedball were the
highest among individuals in class 4 compared to all other classes, and the probability
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of being 42 years old or above were very high (>99%). We referred to class 4 as
“persons >=42 years old who used>6 drugs”.
Table 3 presents the results of our bivariate multinomial logistic regression. We found
that only HCV status was significantly associated with drug use latent classes.
Compared with the members in other classes, class 4 members had the highest
possibility of having HCV infection. The odds of having HCV infection among class 4
members was 14 times (OR=14.2, 95%CI: 1.3-157.4) the odds of having HCV infection
among those who in class 2, and was 20 times (crude OR=20.5, 95%CI: 1.4-291.7) the
odds of having HCV infection among those who in class 3. The probability of having
HCV also showed higher in class 4 members than class 1 members, but the results was
not statistically significant (crude OR=7.8, 95%CI: 0.5-134.7). For the associations
between drug use classes with other variables, such as sociodemographic
characteristics, sexual behaviors, self-reported STI history, blood transfusion history,
and occupational blood exposure history, all the results were not statistically significant.
Table 4 presents the results of our multivariable regression model. We entered drug
treatment history, self-reported STI history and trading money or drugs for sex in the
past month in the model (these variables had p-values<0.25 in the bivariate analysis) to
adjust for the association between drug use class and HCV infection. The results
showed that HCV infection status was significantly associated with drug use classes.
Compared with class 2 members, class 4 members had close to 17 times the odds of
having HCV infection (adjusted OR = 16.9, 95%CI: 1.4-205.4), and compared with class
3 members, class 4 members had close to 22 times the odds of having HCV infection
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(adjusted OR=21.8, 95%CI: 1.5-322.8), controlling for drug treatment history, selfreported STI history and trading money or drugs for sex in the past month.
DISCUSSION
In this study, we applied LCA to identify latent classes among MSM who reported drug
use but did not report injection use of drugs. We found four distinct latent classes, which
were class 1, persons >=42 years old who used only crack cocaine; class 2, persons
about 42 years old who used >2 drugs; class 3, persons <42 years old who used >5
drugs; and class 4, persons >=42 years old who used >6 drugs. We also found
associations between certain latent classes of drug use and HCV infection. After
adjusting for drug treatment history, self-reported STI history, and behavior of trading
money or drugs for sex in the past month, we found that persons >=42 years old who
used >6 drugs had close to 17 times the odds of having HCV infection, compared with
persons about 42 years old who used >2 drugs, and close to 22 times the odds of
having HCV infection, compared with persons <42 years old who used >5 drugs.
Among participants who were 42 years old or above, the membership of drug use latent
class was polarized. Members in one class (class 1) only used crack cocaine, whereas
members in the other class (class 4) used multiple drugs, including crack cocaine,
marijuana, powder cocaine, methamphetamine, heroin, and speedball. The members in
class 4 had a higher HCV infection probability than those who were in class 1, but the
difference was not statistically significant. However, we need to interpret this nonsignificant result cautiously, because the sample sizes in the two classes accounted for
only 3.2% and 6.5% of the sample, respectively, which limited the statistical power of
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the study to detect the differences in HCV infection probabilities between these two
classes.
The mean age for the class 3 members was slightly lower than that for the class 2
members. The class 3 members had higher probability of using fry and codeine than the
class 2 members, which is consistent with previous reports in the 1990s of fry (ModestoLowe & Petry, 2001; Peters Jr et al., 2005) and codeine abuse (Elwood, 2001; Peters Jr
et al., 2007), especially among teenagers. The results of the present study showed that
compared with participants who used crack cocaine and marijuana, those who
additionally used fry and codeine did not have a higher probability of HCV infection. One
reason may be that people normally take fry by smoking it and codeine in the form of
syrup, pill, or drinks (mixed with soda). All these administrative routes have a lower
likelihood of blood exposure that may lead to HCV infection and transmission. However,
studies have reported an increase of sexual risk behavior among people who use of fry
or codeine (Peters Jr et al., 2007), but these studies were not restricted to MSM. The
present study, which was restricted to MSM, found that the use of fry or codeine were
not associated with sexual risk behaviors.
By comparing latent classes of drug use with different ages, we found an interaction
effect between age and drug use types on the probability of HCV infection. This finding
indicates that age and drug use types were both associated with HCV infection, and that
differences in age were linked to different preference of drug use types. The participants
who had multiple use of heroin, speedball, and methamphetamine, in addition to the
commonly used crack cocaine and marijuana, were all 42 years old or above, which
formed a latent class that had a much higher HCV infection probability than that of other
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latent classes. On the one hand, some previous studies revealed that individuals born
between 1945-1965 had a higher HCV infection rate than that of other individuals;
conversely, other previous studies implied that the use of heroin, speedball, and
methamphetamine may relate to HCV infection from several perspectives. First,
repeated intranasal use of heroin, cocaine (speedball is heroin mixed with cocaine), and
methamphetamine may cause mucosal trauma and hyperemia (Bakhshaee, Khadivi,
Sadr, & Esmatinia, 2013; Blaise, Vanhooteghem, & De La Brassinne, 2007; Peyrière et
al., 2013; Trimarchi et al., 2006), and HCV has been detected in nasal secretions
(Aaron et al., 2008) in people with HCV infection. Second, drug use paraphernalia are
often shared among people who use drugs, and HCV RNA may remain in the
paraphernalia for up to 16 hours (Kamili, Krawczynski, McCaustland, Li, & Alter, 2007).
Third, people who use heroin, speedball, and methamphetamine may be exposed to
social networks with a higher HCV infection rate than those who use other drugs,
because a proportion of people who use heroin, speedball, and methamphetamine
inject these drugs, and 40%-90% of people who inject drugs are infected with HCV
(Gerberding, 1994; Hagan, Pouget, Des Jarlais, & Lelutiu-Weinberger, 2008). However,
some studies have not found that sharing straws or dollar bills when snorting drugs
among people who do not report injection drug use is associated with HCV infection
(Gyarmathy, Neaigus, Miller, Friedman, & Jarlais, 2002; Howe et al., 2005). More
research is needed to determine whether sharing equipment for non-injection drug use
is a transmission route of HCV or not.
We cannot directly compare the present LCA findings with those of previous LCA
findings because of different recruitment strategies, indicator variables, and the disease
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of interest. However, our findings are consistent with other findings demonstrating high
rates of infectious diseases, such as HIV, among people who used multiple drugs
(Buchacz et al., 2000; Chitwood, Comerford, & Sanchez, 2003; Drumright & Colfax,
2009; Vallejo et al., 2008). LCA studies in MSM have demonstrated that multiple drug
use is also associated with increased transmission of STIs by disinhibiting sexual risk
behavior (Lim et al., 2015; Yu et al., 2015); the present study did not find as association
between multiple drug use and STIs. One reason of this lack of association may be that
individuals with HIV and/or HBV infection were excluded from the baseline data of
DASH project, which may in turn, lead to the exclusion of individuals also coinfected
with STIs; thus, underestimating the effect of multiple drug use on STIs or risky sexual
behavior in our sample of MSM.
This study had some limitations. First, we had small sample size for some drug use
subgroups identified by LCA. During analysis, we tested multiple combinations of
different variable classifications, and only the reported subgroup solution showed a
significant association with HCV infection. However, although was statistically
significant, it also had very large confidence intervals for the significant results; thus, we
must interpret the results with caution. Second, for some variables assessing sexual risk
behaviors, this study might not have sufficient power to identify their effects on HCV
transmission. Third, the route of drug use, and information regarding sharing equipment
for drug use were not collected in this study, which may provide crucial information on
HCV transmission route in this population (Tortu, McMahon, Pouget, & Hamid, 2004).
Fourth, although drug use was verified by lab testing, drug use types and sexual risk
behaviors were self-reported, which may have led to underreporting. Fifth, the cross-
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sectional study design may not confirm the temporality of the risk behaviors and HCV
infection. Lastly, some information potentially related to sexual transmission of HCV was
not collected in this study, e.g., drugs related to sex (MDMA, LSD, etc.), and sexual
behaviors such as anal sex and group sex. Future studies are warranted with larger
sample size, collecting additional information on administrative routes of drug use, sexrelated drugs, and detailed sexual risk behaviors of MSM. Further, a longitudinal study
design may help clarify the temporality of risk behaviors and HCV infection and explore
the transition between drug use subgroups, which may provide insightful understanding
of association between drug use behavior and the risk of HCV infection.
Despite these limitations, this study has several strengths. To the best of our
knowledge, this is the first study to evaluate the association of latent class of noninjection drug use and HCV infection among HIV-negative MSM by using latent class
analysis. Because LCA reduced the dimension of drug use types, this study discovered
and evaluated the interaction effect between age and multiple drug use types on HCV
infection, which very few studies have reported. In addition, this study excluded
individuals with HIV and/or HBV infection; thus, although it led to a smaller sample size
for this study, we demonstrated that in the absence of HIV and HBV, there was still a
strong association between the interaction of age and multiple drug use types on HCV
infection.
In conclusion, we found four distinct latent classes of drug use among MSM: (1)
persons >=42 years old who used only crack cocaine, (2) persons about 42 years old
who used >2 drugs, (3) persons <42 years old who used >5 drugs, and (4) persons
>=42 years old who used >6 drugs. Persons >=42 years old who used >6 drugs was
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associated with increased probability of HCV infection. Health education and promotion
programs geared towards this subgroup of MSM are needed to increase the awareness
of HCV infection, and subsequently increase testing and treatment rates for HCV.
Furthermore, drug treatment programs or rehabilitation programs are also needed to
reduce the physical damage of multiple drug use and the probability of acquiring or
transmitting HCV, especially among heavy multiple drug use MSM.
Funding
This study was funded by The National Institute of Drug Abuse (NIDA#
1R01DA017505).
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Table 1 Characteristics of 118 HIV-negative MSM who reported drug use but did not
report injection drug use in Houston, TX
Characteristics

n

%

116

98.3

17

14.4

Marijuana

105

89.0

Alcohol

101

85.6

Fry

25

21.2

Powder cocaine

67

56.8

Heroin

8

6.8

Speedball

4

3.4

Codeine

26

22.0

42 years old or above

59

50

African American

98

83.1

Self-reported homosexual or bisexual

98

83.1

Education level (less than or equal to high school)

90

76.3

Marital status (single)

77

65.3

Worked less than 14 days in past 30 days

58

49.2

Income less than 400 dollars in the past month

70

59.3

Homeless

54

45.8

Had been in jail for more than 24 hours

90

76.3

Never received drug treatment

41

34.7

Had 0 or 1 male sexual partner in the past month

48

40.7

Condom use frequency (<=50%)

71

60.7

Traded sex for money or drugs in the past month

74

62.7

Traded money or drugs for sex in the past month

68

57.6

53

44.9

Had blood transfusion history

4

3.4

Had occupational blood exposure history

7

5.9

Latent class indicators a
Crack cocaine
Methamphetamine

Sociodemographic characteristics

Sexual behaviors

Diseases status
Had sexual transmitted disease history
Blood exposure

a These variables refer to the response to the question: “have you ever used this drug”
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Table 2 Statistics and entropy of latent class analyses
LLa

Free
parameters

BICb

LMRc

BLRTd

Entropy

1

-462.630

10

972.966

NA

NA

NA

2

-430.427

21

961.039

0.0001

0.0000

0.731

3

-418.644

32

989.950

0.0177

0.0100

0.957

4

-406.801

43

1018.742

0.0424

0.0400

0.963

5

-400.104

54

1057.826

0.0115

0.4000

0.957

6

-394.546

65

1099.186

0.1469

0.6200

0.978

classes
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Table 3 Bivariate associations between latent class membership and characteristics of 118 HIV-negative MSM who
reported drug use but not injection drug use in Houston, TX
Characteristics

Class 4 vs 1 Class 4 vs 2
cOR (95%CI)* cOR (95%CI)

Class 4 vs 3
cOR (95%CI)

Class 1 vs 2
cOR (95%CI)

Class 1 vs 3
cOR (95%CI)

Class 3 vs 2
cOR (95%CI)

African American vs
Caucasian or Hispanic

14621447
(0.0-I)

1.5
(0.1-16.3)

2.7
(0.2-40.2)

0.0
(0.0-I)

0.0
(0.0-I)

0.5
(0.1-2.4)

Homosexual or bisexual vs
heterosexual

0.0
(0.0-I)

0.0
(0.0-I)

0.0
(0.0-I)

2.2
(0.4-12.7)

0.9
(0.1-6.3)

2.3
(0.7-7.2)

Less than or equal to high school vs
higher than high school

0.0
(0.0-I)

0.4
(0.0-3.7)

0.3
(0.0-3.1)

9175065
(0.0-I)

6382051
(0.0-I)

1.4
(0.4-4.7)

Single vs
married, live with partner, separated, divorced,
widowed

20.5
(0.02.12E189)

5.5
(0.5-58.6)

4.0
(0.3-47.6)

0.3
(0.0-2.75E187)

0.2
(0.0-2.03E187)

1.4
(0.5-3.6)

Days of working in the past month:
<14 days vs >=14 days

1980777
(0.0-I)

17175594
(0.0-I)

27371147
(0.0-I)

8.7
(0.0-1.99E192)

13.8
(0.0-3.17E192)

0.6
(0.2-1.7)

Income in the past month:
<400 dollars vs >= 400 dollars

11.6
(0.0-I)

64.8
(0.0-I)

85.0
(0.0-I)

5.6
(0.0-2.27E198)

7.3
(0.0-2.98E198)

0.8
(0.3-2.0)

Ever homeless vs never homeless

0.2
(0.0-3.4)

0.4
(0.0-4.4)

0.5
(0.0-6.2)

2.0
(0.4-9.7)

2.5
(0.4-14.3)

0.8
(0.3-2.1)

Had been in jail for more than 24 hours:
Yes vs No

7195742
(0.0-I)

4239687
(0.0-I)

2340792
(0.0-I)

0.6
(0.1-3.0)

0.3
(0.0-2.2)

1.8
(0.5-6.3)

Never received drug treatment vs
received drug treatment

0.7
(0.0-12.0)

0.6
(0.1-6.2)

1.2
(0.1-15.6)

0.8
(0.1-4.6)

1.8
(0.3-12.1)

0.5
(0.2-1.5)

No. of male sexual partners in the past month:
0 or 1 vs >1

0.0
(0.0-I)

0.0
(0.0-I)

0.0
(0.0-I)

1.2
(0.2-6.1)

1.0
(0.2-5.6)

1.2
(0.5-3.3)

Condom use frequency while having sex:
<=50% vs >50%

0.7
(0.1-10.0)

0.8
(0.1-7.2)

0.6
(0.1-5.8)

1.1
(0.2-5.2)

0.8
(0.1-4.5)

1.4
(0.5-3.9)

Sociodemographic

Sexual behavior
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Characteristics

Class 4 vs 1 Class 4 vs 2
cOR (95%CI)* cOR (95%CI)

Class 4 vs 3
cOR (95%CI)

Class 1 vs 2
cOR (95%CI)

Class 1 vs 3
cOR (95%CI)

Class 3 vs 2
cOR (95%CI)

Traded sex for money or drugs in the past
month
Yes vs No

2.8
(0.2-42.8)

1.7
(0.2-17.8)

1.3
(0.1-16.0)

0.6
(0.1-2.9)

0.5
(0.1-2.7)

1.2
(0.5-3.4)

Traded money or drugs for sex in the past
month
Yes vs No

2.5
(0.2-39.1)

2.3
(0.2-24.6)

1.2
(0.1-14.9)

0.9
(0.2-4.5)

0.5
(0.1-2.9)

1.9
(0.7-5.2)

Had blood transfusion
Yes vs No

12310954
(0.0-I)

14.7
(1.0-220.7)

9.7
(0.03.07E257)

0.0
(0.0-I)

0.0
(0.0-I)

1.5
(0.04.83E256)

Had occupational blood exposure
Yes vs No

2.0
(0.0-I)

0.0
(0.0-I)

6.3
(0.0-I)

0.0
(0.0-I)

3.1
(0.0-I)

0.0
(0.0-I)

Had STI***
Yes vs No

1.6
(0.1-25.4)

4.4
(0.4-46.4)

2.1
(0.2-25.0)

2.8
(0.5-14.0)

1.4
(0.2-7.9)

2.1
(0.8-5.4)

Had HCV infection
Yes vs No

7.8
(0.5-134.7)

14.2 **
(1.3-157.4)

20.5 **
(1.4-291.7)

1.8
(0.3-10.6)

2.6
(0.3-21.8)

0.7
(0.2-3.0)

Blood exposure history

Disease history

* cOR: crude odds ratio
** P<0.05
*** STI: Sexually transmitted infections
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Table 4 Multivariable association between latent class membership with characteristics in 118 HIV-negative MSM who
reported drug use but not injection drug use in Houston, TX
Characteristics

Class 4 vs 1
aOR* (95%CI)

Class 4 vs 2
aOR (95%CI)

Class 4 vs 3
aOR (95%CI)

Class 1 vs 2
aOR (95%CI)

Class 1 vs 3
aOR (95%CI)

Class 3 vs 2
aOR (95%CI)

Never received drug treatment vs
received drug treatment

0.8
(0.0-17.0)

0.7
(0.1-9.8)

1.2
(0.1-19.7)

0.9
(0.1-5.1)

1.5
(0.2-11.0)

0.6
(0.2-1.9)

Had STIs*** vs Never had STI

1.9
(0.1-33.5)

5.3
(0.4-65.3)

2.7
(0.2-36.6)

2.8
(0.5-14.6)

1.4
(0.2-8.6)

2.0
(0.7-5.3)

Traded money or drugs for sex in the
past month vs never traded money or
drugs for sex in the past month

2.5
(0.1-48.4)

2.4
(0.2-33.2)

1.4
(0.1-21.6)

1.0
(0.2-4.8)

0.6
(0.1-3.4)

1.7
(0.6-5.0)

Had HCV infection vs Did not have
HCV infection

8.5
(0.5-154.0)

16.9 **
(1.4-205.4)

21.8 **
(1.5-322.8)

2.0
(0.3-12.2)

2.6
(0.3-22.2)

0.8
(0.2-3.5)

* aOR: adjusted odds ratio
** P<0.05
*** STI: Self-reported sexually transmitted infections
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Screened
N=2800

Not enrolled
HIV (+) or HBV (+)
N=1540

Enrolled
N=1260

IDU
N=410

NIDU
N=850

Not MSM
N=732

MSM
N=118

Figure 1. DASH study population flow chart
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Figure 2 Probability of each indicator variable in each class of 4-latent class model
Note:
Class 1 (6.5%): persons >=42 years old who used only cruck cocaine;
Class 2 (70.3%): persons about 42 years old who used >2 drugs;
Class 3 (20.1%): persons <42 years old who used >5 drugs;
Class 4 (3.2%): persons >=42 years old who used >6 drugs.
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Article III: Risk factors associated with HCV infection in young men who have
sex with men reporting drug use not including inject drug in Houston, TX
This article has been formatted for the Journal of BMC Public Health

ABSTRACT
Background: Hepatitis C (HCV) infection in men who have sex with men (MSM)
has been increasingly reported in recent years. However, little is known about HCV
infection in young MSM (YMSM).
Methods: From 2014 to 2017, we recruited YMSM (aged between 17-29 years) who
reported drug use, but not injection drug use, in Houston, Texas. We collected
information on sociodemographic characteristics and sexual risk behaviors of
participants and their sexual partners. We also tested participants for HIV, syphilis,
and anti-HCV. Generalized estimating equations were used to assess the
association between HCV infection and a variety of exposures.
Results: Among 983 participant-partner dyads, we found that syphilis/HIV
coinfection was significantly associated with having anti-HCV of the participants.
Compared with the odds of having anti-HCV among reference group (participants’
syphilis mono-infection, HIV mono-infection, and neither syphilis nor HIV infection),
the odds of having anti-HCV among syphilis/HIV co-infected participants is 4.5times
higher (aOR=4.5, 95%CI: 1.05-18.76), controlling for age similarity, participants’ HIV
status, and whether the participant and his sexual partner used drug before sex.
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Conclusion: Syphilis/HIV co-infection was all associated with increased HCV
infection. Treatment of syphilis and/or HIV may reduce the disease burden of HCV in
YMSM who reported drug use not including injection drug use.

INTRODUCTION
Since 2000, there have been increasing reports of a hepatitis C virus (HCV)
epidemic and outbreaks among HIV-positive men who have sex with men (MSM) in
Northern Europe, North America, and Australia [1-4]. One meta-analysis reported
that the pooled estimated incidence rate of HCV infection among HIV-positive MSM
was 19 times that among HIV-negative MSM [5]. Another meta-analysis reported
that the pooled HCV prevalence is 8.1% [6], much higher than that in the rest of the
general population in the United States (1%) [7]. The epidemic of HCV in MSM has
been linked to high-risk sex behaviors, such as group sex with unprotected anal
intercourse (UAI) [4, 8], fisting [4, 9]; rectal trauma with bleeding [10]; and potentially
underreported non-injection drug use [9, 11, 12].
“Chemsex” is the use of drugs before or during sex to enhance sexual arousal,
performance and disinhibition. It has been shown to influence sexual risk behaviors
in this population [13-16]. In recent years, a growing number of studies reported
chemsex in MSM, and found that the prevalence of chemsex ranged from 3% to
29% among MSM recruited from public venues, gay venues, gay pride event, sexual
health clinic, internet, and so on [17]. Chemsex is associated with sexual risk
behaviors, including UAI [17-19], being fisted [19, 20], and group sex [20]. Chemsex
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is also associated with new HIV infection [21], acute sexually transmitted infections
(STI) [18, 21, 22], and HCV infection [18, 21, 23].
Besides “chemsex”, MSM also disproportionately shared the disease burden of
syphilis and HIV. The incidence of syphilis and HIV infection in MSM [24, 25],
especially in young MSM (YMSM) have been increasing in recent years, which might
also contribute to the reported epidemic of HCV in MSM. In the United States,
reported primary and secondary (P&S) syphilis increased 10.5% between 2016 and
2017 [26]. Males accounted for more than 90% of new cases of syphilis infection
from 2009 to 2013, among whom, MSM who were 25-29 years old had the greatest
increase among all age groups (48.4%, 18.2 to 27.0 per 100,000 population) [27].
Moreover, for the incidence of HIV infection in the United States, MSM accounted for
two thirds of new infections in 2010 [28]. In reported cases from 2008 to 2011, MSM
who were aged 25-34 years accounted for the highest proportion, while MSM aged
13-24 years had the fastest growing rate of infection [29].
Although research on the sexual transmission of HCV in MSM has increased, most
studies have focused on HIV-positive MSM and/or MSM who inject drugs. In
addition, little is known of HCV risk factors specific to YMSM, which may be a
particularly vulnerable subgroup of MSM. Furthermore, most of the information used
in such studies is at an individual level, which may not adequately reflect the
dynamics of disease transmission. To fill this knowledge gap, we analyzed
participant-partner dyadic data of YMSM who reported drug use not including
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injection drug use, a subset from the parental study of the Young Men Affiliation
Project (YMAP). According to Neaigus, the dyadic link is the primary unit in network
development; thus, dyadic data analysis may yield useful results and is feasible
among hidden populations, such as MSM [30]. The objective of the study is to
assess the associations between the characteristics of participants, sexual partners
and characteristics of partnership in a subset of egocentric sexual networks of
YMSM and the likelihood that participants are infected with HCV.
METHODS
Study setting
Data were obtained from the Young Men’s Affiliation Project (YMAP), a longitudinal
network study collected from 2014 to 2017 to investigate social networks and
attendance history at social venues and health-promoting venues among YMSM,
and to determine how these networks affect HIV and sexually transmitted disease
risk and prevention in Houston and Chicago [31-33]. For Houston site, participants
were included in this study if they identified as male sex assigned at birth and
current male identification, were aged between 17-29 years, reported oral or anal
sex with another male in the past 12 months, were residing in and planning to
remain in Houston for the following year, and were English-speaking. The study was
approved by the institutional review boards at each institution (HSC-SPH-12-0830).
Participant recruitment and data collection
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The sampling method in the YMAP study was respondent driven sampling (RDS)
[34]. This method has been applied to recruit hard-to-reach populations, such as
MSM and people who use drugs. The “seeds” were defined as participants enrolled
via representatives at health service providing facilities or at social venues. “Sprouts”
were defined as participants who were referred by “seeds”. Four vouchers were
given to each participant to recruit other YMSM (sprouts) to produce chained
samples.
Interviews were conducted using a computer-based personal-interview combined
with a computer-assisted self-interview delivered via Qualtrics (Qualtrics LLC, Provo,
Utah). In the computer-assisted personal interviews, the trained data collector read
questions from the computer and entered data. We collected information on
sociodemographic characteristics, drug use, social and sexual networks, behavior
with peers, and participants’ affiliation with community organizations and
businesses. For sexual networks, each participant was asked to nominate up to 5
sexual partners in the past 6 months. We collected participants’ perception of each
sexual partner’s sociodemographic characteristics, behavioral measures, HIV status,
as well as partnership-level information between the participant and each of his
partner’s sexual behavioral measures.
Laboratory testing
After the interview, each participant provided biological blood specimen for HIV,
HCV, and syphilis testing. HIV tests included fourth generation rapid test, using
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Alere Determine HIV-1/2 Ab/Ag combo (Abbott Laboratories, Chicago, IL), viral load
quantitative test, using Cobas AmpliPrep/Cobas TaqMan HIV-1 test kit, version 2,0
(Roche Molecular Diagnostics, Pleasanton, California), and confirmatory test, using
Geenius HIV -1/2 Confirmatory test (Bio-rad, Marnes-la-Coquette, France). Syphilis
tests included a rapid plasma regain (RPR) test, using the Macro-Vue RPR Card test
Kit (BD Diagnositics, Franklin Lakes, New Jersey), and fluorescent treponemal
antibody FTA test, using Immunofluorence Assay FTA-Absorption Test System
(Zeus Scientific, Branchburg, New Jersey). HCV test was HCV antibody rapid test
(Boson Biotech, Xiamen, China).
HIV infection was defined as rapid test positive and viral load detectable, or viral
load undetectable but confirmation test positive. Syphilis infection was defined as
FTA test positive and RPR titer equal to or greater than 1:8. [35] HCV infection was
defined as repeated positive results from rapid antibody test.
Study sample and measures
The study sample was a subset of YMAP baseline data restricted to participants who
reported never having injected drugs. The outcome variable was participant’s HCV
status and the independent variables included three sets: (a) participant’s
characteristics, (b) perceived sexual partner’s characteristics, and (c) dyadic
measures between a participant and each of his sexual partner’s sexual behaviors.
For participants’ measures, we used sociodemographic information (age, education
level, race/ethnicity, employment status, living arrangement, insurance status, and
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have ever been in jail for more than 24 hours), sexual risk behavioral information
(group sex and number of sexual partners in the past 6 months), and disease status
(HIV and syphilis infection status). For participants’ perception of sexual partner’s
characteristics, all data were treated as clustered data on the participant, including
sociodemographic information (age, gender, education level, and race/ethnicity), and
sexual risk behavioral information (unprotected sex, HIV infection status and drug
use). For participants’ perception of sexual network dyadic measures, all data were
also treated as clustered data on the participant, including sexual behavioral
measures (whether shared drugs, times that had sex, whether had anal sex,
whether the participant ever had receptive anal sex, consistent condom use,
whether used drugs before sex, whether engaged in group sex together) and
homophily/similarity measures with respect to age, race/ethnicity, and HIV
serostatus. We defined age homophily as the value of age difference between a
participant and his nominated sexual partner; race/ethnicity homophily as 1=black
with black, 2=black with non-black or non-black with black (dissortativity), and
3=non-black with non-black; and HIV serostatus homophily as 1= participant HIV
seropositivity and participant’s perception about sexual partner’s positivity,
2=participant HIV seropositive and participant’s perception about sex partner
negative, 3=participant HIV seropositivity and participant’s perception about sex
partner’s unknown, 4=participant HIV seronegative and participant’s perception
about sex partner positive, 5=participant HIV seronegative and participant’s
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perception about sex partner negative, and 6=participant HIV seronegative and
participant’s perception about sex partner unknown.
Statistical analysis
The unit of analysis was the sexual dyad, which was a pair composed of a
participant and each of his nominated sexual partners. We conducted Chi-square
tests and Fisher exact tests to assess the differences of HCV status between the
categories of each independent variable. We also conducted bivariate and
multivariable generalized estimating equation (GEE), which can deal with clustered
observation of participants[36] to statistically test the association between HCV
status and independent variables. We used autoregressive correlation structure and
robust estimates to address potential misspecification of variance structure. Bivariate
analyses were performed between HCV status and each independent variable,
showing crude odds ratio and 95% confidence intervals. For variables with p-values
less than 0.25 in bivariate analyses, we included all of them, except syphilis monoinfection, into multivariable GEE model. We excluded syphilis mono-infection
because this variable and syphilis/HIV co-infection had collinearity. We finally
assessed the interaction effect between the selected independent variables in a
multivariable model. The statistical significance level was set at 5%. We used SAS
9.4 (Cary, NC) to manage the data and conduct the GEE analysis.
RESULTS
Participants’ characteristics
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Among 378 participants of YMAP study, we excluded 5 participants who reported
never used any drugs, 4 participants who reported injection drug use behavior, 3
participants who did not report injection drug use information. We finally identified a
total of 366 MSM who reported drug use not including injection drug use, among
whom 12 (3.3%) had anti-HCV. Table 1 shows the characteristics of participants
stratified by HCV status. In terms of sociodemographic characteristics, age ranged
from 17 years to 29 years with a median of 25 years. Of the participants, 63% had
more than a high school education level; 63% were black; 19% were Hispanic; 49%
were employed;18% were homeless in the past month; 59% had insurance; and
40% had ever been in jail for more than 24 hours. In terms of sexual risk behaviors,
28% engaged in group sex; 44% had 2 to 5 sexual partners in the past 6 months. In
terms of disease status, 38% were HIV positive and 16% were syphilis positive; 12%
were co-infected with HIV and syphilis. Chi-square or Fisher exact tests show that
HCV status differed significantly between HIV-positive and HIV-negative
participants, as well as between positive syphilis and negative syphilis participants.
Participants’ sexual partners’ perceived characteristics and dyad measures
A total of 983 sexual partners were nominated by participants. Table 2 shows the
participants’ perceived characteristics of sexual partners and dyadic measures
between a participant and his sexual partners stratified by participants’ HCV status.
For socio-demographic characteristics of sexual partners, age ranged from 19 years
to 65 years, with a median of 26 years; 92% were male; 50% had more than a high
school education level; 51% were black; 22% were Hispanic. For behavioral
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measures and disease status of sexual partners, 44% had unprotected sex; 11%
were participant perceived HIV positive and 27% had unknown HIV status by
participants; 39% used drugs. For dyadic measures between participants and their
sexual partners, 29% shared drugs with participants; 42% had sex 2 to 9 times with
participants; 88% had anal sex with participants; 52% let participants ever had
receptive anal sex; 36% had consistent condom use when having sex with
participants; 30% used drugs before sex; 8% had group sex together with
participants. For the perceived characteristics of homophily, 70% of the dyads had
participants’ age younger than sexual partners’ age; 47% of the dyads were black for
both participants and sexual partners; 8% of the dyads were both HIV-positive and
49% were both HIV-negative. The results of Chi-square or Fisher exact tests
showed that HCV status differed significantly in the categories of age homophily and
HIV status homophily: a participant who was older than his sexual partner had
higher probability of having anti-HCV than the participant who was younger than his
sexual partner; a participant who was HIV positive regardless of his sexual partner’s
HIV status perceived by the participant, had higher probability of having anti-HCV
than an HIV-negative participant regardless of his sexual partner’s HIV status
perceived by the participant. Additionally, whether the participants and sexual
partners shared drugs (p=0.071) and used drugs before sex (p=0.077) had small pvalue in Chi-square tests.
Bivariate and multivariable analyses
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For the results of the bivariate GEE model, Table 3 shows the crude odds ratio,
95%CI, and p-value of Wald tests of each independent variable. As shown, HIV
status and syphilis status were significantly associated with HCV status (HIV
cOR=5.31, 95%CI: 1.5-19.3; syphilis cOR=6.6, 95%CI: 1.8-23.8). Age homophily (pvalue=0.12) and whether the participant and his sexual partner used drugs before
sex (p-value=0.19) both had p-values less than 0.25, so they were included in the
multivariable model.
For the multivariable GEE model, we included age homophily, HIV status, syphilis
status, and whether the participant and his sexual partner used drugs before sex in
the model. As in the bivariate GEE model, there was an interaction effect between
HIV status and syphilis status, so we used the interaction variable of HIV and
syphilis status in the final model. Table 4 shows the adjusted odds ratio and 95%CI
in multivariable GEE model. As shown, syphilis/HIV coinfection was significantly
associated with having anti-HCV of the participants. Compared with the odds of
having anti-HCV among reference group (participants’ syphilis mono-infection, HIV
mono-infection, and neither syphilis nor HIV infection), the odds of having anti-HCV
among syphilis/HIV co-infected participants is 4.5 times higher (aOR=4.5, 95%CI:
1.05-18.76), controlling for age similarity, participants’ HIV status, and whether the
participant and his sexual partner used drug before sex.
DISCUSSION
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In this study, we examined the sociodemographic characteristics and sexual risk
behaviors of YMSM and their sexual partners to determine risk factors of having
anti-HCV in this potentially vulnerable subpopulation. We found HIV/syphilis coinfection, was significantly associated with participants’ anti-HCV, while controlling
for age homophily between the participant and his sexual partner, participants’ HIV
status, and whether the participant and his sexual partner used drugs before sex.
Syphilis infection was found to be associated with HCV infection. This finding is
consistent with the findings of two studies among women in Chicago and India,
which reported syphilis infection independently associated with HCV infection [37,
38]. Similar studies among MSM were mostly restricted to HIV-positive MSM, one of
which indicated that syphilis infection increased the risk of HCV infection about 5
times in HIV-positive MSM [39]. In addition, HIV mono-infection has also been found
to be associated with HCV infection. A systematic review showed the risk of HCV
infection was 19 times higher among HIV-positive MSM than that among HIV
negative MSM[5]. The results of the present study were consistent with prior studies,
showing that syphilis mono-infection and HIV mono-infection were associated the
increased probability of HCV infection.

Our study indicates that the syphilis/HIV coinfection group had the highest risk of
having anti-HCV compared to the risk of having anti-HCV in mono-infection groups,
and syphilis/HIV coinfection had more than additive interaction effect on HCV
infection. This finding suggests that there is a link between HIV infection and syphilis
88

infection, which is consistent with prior studies. In the United States, about half of
syphilis-infected MSM are living with HIV; those who are mono-infected with syphilis
have a 2- to 5- fold increase of HIV infection than those who are uninfected with
syphilis[26]. The biological explanations of the overlapped epidemic are syphilis
infection may cause sores, ulcers or breaks in the skin or mucous membranes that
provide protection against infection[40]. HIV infection causes suppression of immune
system. All the aforementioned mechanisms can also be used to explain the effect
of syphilis/HIV infection on HCV infection transmitted by blood exposure or fluid
contact.

All sociodemographic and risk sexual behaviors at both the individual and dyadic
level were not statistically significant in this study. However, it is worth noting that
using drugs before sex between the participant and his sexual partner (also referred
to as “chemsex”) had a smaller p-value (p=0.19) than other sociodemographic and
risk sexual behavior measures. Although this variable is not statistically significant in
this study, it is of increasing concern in large MSM communities[41]. Prior studies
reported that chemsex is associated with HCV infection [18, 21, 23]. However, none
of the studies were restricted to YMSM. To better evaluate the effect of “chemsex”
on HCV infection in YMSM, further study may include drug use during sex in addition
to before sex, and expand the question to any sexual partner instead of restricting to
nominated sexual partner, which may collect information on “chemsex” to a greater
extent.

89

This study has several limitations. First, we may not know the HCV status of sexual
partners, and thus, cannot provide direct evidence of HCV transmission by sexual
behavior. Second, the anti-HCV rate is relatively low in this YMSM population, which
may compromise the statistical power. Third, the cross-sectional design of the study
cannot provide temporality information to establish causality. Lastly, detailed
information on sharing equipment of non-injection drugs was not collected in this
study, which could be a risk factor of HCV infection. In order to elucidate HCV
transmission in YMSM who reported drug use not including injection drug, further
study is needed concentrated on MSM, with a larger sample size, with efforts to
obtain HCV infection status for both the respondent and the sexual partner and
information on sharing equipment of non-injection drugs.
Despite the limitations mentioned above, this study has multiple strengths. First, this
study analyzed dyadic data, which may provide insightful information among sexual
partners regarding HCV infection. By incorporating and evaluating dyadic data, this
study may infer characteristics of HCV transmission dynamics. Second, the study
population, YMSM, represents a growing HCV susceptible subgroup, and the study
results may add evidence of the emerging HCV epidemic in MSM in recent years.
Third, the HIV, HCV, and syphilis infection status of participants were confirmed by
lab test, not self-reported, which reduced the information bias.
In conclusion, we found syphilis mono-infection, HIV mono-infection and syphilis/HIV
co-infection were associated with increased risk of HCV infection among a sample of
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YMSM living in Houston, who reported drug use not including injection drug use.
Health education and promotion programs geared towards raising the awareness of
HCV testing and treatment in HIV and/or syphilis infected YMSM may help reduce
the disease burden of HCV directly. Also, programs targeting an increase in syphilis
and HIV testing and treatment among YMSM may potentially reduce the
transmission HCV in YMSM.

Table 1 Sociodemographic characteristics and sexual risk behaviors of YMSM
participants in Houston, TX (N=366)
Covariates
Total
Age
<25
≥ 25
Education level
High school or less
Above high school
Hispanic
Yes
No
Race

Total

HCV+

HCV-

Fisher test
P value

366 (100) 12 (3.3) 354 (96.7)
0.519*
186 (50.8)
180 (49.2)

5 (2.7) 181 (97.3)
7 (3.9) 173 (96.1)

135 (36.9)
231 (63.1)

4 (3.0) 131 (97.0)
8 (3.5) 223 (96.5)

70 (19.1)
296 (80.9)

3 (4.3) 67 (95.7)
9 (3.0) 287 (97.0)

0.795

0.599

0.917

Black
White
Multiracial, other
Working status
Full time
Part time

230 (62.8)
83 (22.7)
53 (14.5)

8 (3.5) 222 (96.5)
2 (2.4) 81 (97.6)
2 (3.8) 51 (96.2)

179 (48.9)
72 (19.7)

7 (3.9) 172 (96.1)
2 (2.8) 70 (97.2)

Not employed
Homeless in the past 12 month
Yes
No
Insurance

115 (31.4)

3 (2.6) 112 (97.4)

65 (17.8)
301 (82.2)

3 (4.6) 62 (95.4)
9 (3.0) 292 (97.0)

0.926

0.505

0.260
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Covariates

Total

HCV+

HCV-

Yes
No
Ever been in jail for more than 24 hours

217 (59.3)
149 (40.7)

Yes
No
Group sex
Yes
No
No. of sexual partners in the past 6 months
0-1

146 (39.9)
220 (60.1)

104 (28.4)

4 (3.8) 100 (96.2)

2-5
>=6
Continuous scale, include mean (SD, min, max)
HIV infection
Yes
No

162 (44.3)
100 (27.3)

5 (3.1) 157 (96.9)
3 (3.0) 97 (97.0)

Fisher test
P value

9 (4.1) 208 (95.9)
3 (2.0) 146 (98.0)
0.637
4 (2.7) 142 (97.3)
8 (3.6) 212 (96.4)
0.838

101 (27.6)
265 (72.4)

3 (3.0) 98 (97.0)
9 (3.4) 256 (96.6)
0.933

0.006
134 (37.1)
227 (62.9)

9 (6.7) 125 (93.3)
3 (1.3) 224 (98.7)

Syphilis infection
<0.001
Yes
56 (15.7) 7 (12.5) 49 (87.5)
No
300 (84.3) 5 (1.7) 295 (98.3)
Syphilis/HIV infection status
<0.001
Syphilis/HIV co-infection
43 (12.1) 6 (14.0) 37 (86.0)
a
Other
313 (25.9) 6 (1.9) 307 (98.1)
* P-value in Chi-square test.
a Other: Syphilis mono-infection, HIV mono-infection, and neither syphilis nor HIV infection
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Table 2 Characteristics perceived by participant of pairs of participants and sexual
partners stratified by participants’ HCV infection status, Houston, TX (N=983)
Covariates

Total

Sexual partner’s characteristics
Gender
Male
Female or transgender
Education
High school or less
Above high school
Unknown
Hispanic
Yes
No
Race
Black
White
Multiracial, other
Unprotected sex
Yes
No
Unknown
HIV infection status
Positive
Negative
Unknown
Ever use drugs
Yes
No
Unknown
Participant and sexual partner’s characteristics
Ever shared drug between the pair
Yes
No
Times that had sex between the pair
2-9
>=10
0-1
Whether had anal sex between the pair
Yes
No

93

HCV+

HCV-

Chisquare
test
P value
0.299*

904 (92.0)
79 (8.0)

31 (3.4) 873 (96.6)
1 (1.3) 78 (98.7)

299 (30.4)
495 (50.4)
189 (19.2)

11 (3.7) 288 (96.3)
18 (3.6) 477 (96.4)
3 (1.6) 186 (98.4)

0.374*

0.630
208 (21.6)
757 (78.4)

8 (3.8) 200 (96.2)
24 (3.2) 733 (96.8)
0.357

501 (51.0)
297 (30.2)
185 (18.8)

19 (3.8) 482 (96.2)
6 (2.0) 291 (98.0)
7 (3.8) 178 (96.2)

436 (44.4)
201 (20.4)
346 (35.2)

12 (2.8) 424 (97.2)
9 (4.5) 192 (95.5)
11 (3.2) 335 (96.8)

108 (11.0)
614 (62.5)
261 (26.6)

6 (5.6) 102 (94.4)
20 (3.3) 594 (96.7)
6 (2.3) 255 (97.7)

0.519

0.276

0.118*
384 (39.1)
378 (38.5)
221 (22.5)

17 (4.4) 367 (95.6)
12 (3.2) 366 (96.8)
3 (1.4) 218 (98.6)
0.071

287 (29.4)
688 (70.6)

14 (4.9) 273 (95.1)
18 (2.6) 670 (97.4)
0.485

398 (41.5)
250 (26.1)
311 (32.4)

13 (3.3) 385 (96.7)
11 (4.4) 239 (95.6)
8 (2.6) 303 (97.4)

852 (88.2)
114 (11.8)

29 (3.4) 823 (96.6)
3 (2.6) 111 (97.4)

0.665*

Covariates

Total

Whether the participant ever had receptive
anal sex
Yes
494 (51.5)
No
465 (48.5)
Consistent condom use between the pair
Yes
352 (35.8)
No
400 (40.7)
Unknown
231 (23.5)
Whether use drugs before sex
between the pair
Yes
292 (29.7)
No
691 (70.3)
Attended group sex together
Yes
81 (8.2)
No
902 (91.8)
Homophily of participants and sexual partners
Age homophily
Participant ≤ Sexual partner
687 (69.9)
Participant > Sexual partner
296 (30.1)
Race homophily
(participant / sexual partner)
Black / Black
447 (45.5)
Black / non-Black
115 (11.7)
non-Black / Black
54 (5.5)
non-Black / non-Black
367 (37.3)
HIV infection status homophily
(participant / sexual partner a)
Positive/Positive
77 (7.9)
Positive/Negative
137 (14.0)
Positive/Unknown
109 (11.1)
Negative/Positive
31 (3.2)
Negative/Negative
475 (48.5)
Negative/Unknown
151 (15.4)
* P-value in Fisher exact test
a Partner’s status as perceived by participant
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HCV+

HCV-

Chisquare
test
P value
0.853

17 (3.4) 477 (96.6)
15 (3.2) 450 (96.8)
0.306*
14 (4.0) 338 (96.0)
14 (3.5) 386 (96.5)
4 (1.7) 227 (98.3)
0.077
14 (4.8) 278 (95.2)
18 (2.6) 673 (97.4)
0.122
5 (6.2) 76 (93.8)
27 (3.0) 875 (97.0)
0.036
17 (2.5) 670 (97.5)
15 (5.1) 281 (94.9)
0.397
18 (4.0) 429 (96.0)
5 (4.3) 110 (95.7)
1 (1.9) 53 (98.1)
8 (2.2) 359 (97.8)
<0.001*
5 (6.5) 72 (93.5)
14 (10.2) 123 (89.8)
6 (5.5) 103 (94.5)
1 (3.2) 30 (96.8)
6 (1.3) 469 (98.7)
0 (0) 151 (100)

Table 3 Results of bivariate GEE model of dyadic data of participant and sexual
partner pairs in Houston, TX (N=983)
Covariates

Unadjusted Odds Ratio P
(95%CI)

Participants’ characteristics
Age
≥ 25
< 25
Education level
High school or less
Above high school
Hispanic
Yes
No
Race
White
Multiracial, other
Black
Working status
Full time
Part time
Not employed
Homeless in the past 12 months
Yes
No
Insurance
Yes
No
Ever been in jail for more than 24 hours
Yes
No
Group sex
Yes
No
No. of sexual partners in the past 6 months
0-1
2-5
>=6
HIV infection status
Yes
No
Syphilis infection status
Yes
No

0.535
1.48 (0.46-4.77)
Reference
0.818
0.87 (0.26-2.94)
Reference
0.694
1.36 (0.36-5.17)
Reference
0.802
0.64 (0.13-3.09)
1.08 (0.22-5.25)
Reference
0.811
1.53 (0.39-6.04)
1.05 (0.17-6.47)
Reference
0.602
1.49 (0.39-5.66)
Reference
0.251
2.05 (0.54-7.70)
Reference
0.643
0.75 (0.22-2.54)
Reference
0.801
0.84 (0.22-3.15)
Reference
0.841
1.52 (0.33-7.00)
1.04 (0.24-4.45)
Reference
0.019
5.64 (1.49-21.29)
Reference
0.020
8.31 (2.53-27.28)
Reference
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Covariates
Syphilis/HIV infection status
Syphilis/HIV co-infection
Other a
Sexual partners’ characteristics
Gender
Male
Female or transgender
Education
High school or less
Unknown
Above high school
Hispanic
Yes
No
Race
White, other
Black
Unprotected sex
Yes
Unknown
No
HIV infection status
Positive
Unknown
Negative
Ever use drugs
Yes
Unknown
No
Participant and sexual partner’s characteristics
Ever shared drug between the pair
Yes
No
Times that had sex between the pair
2-9
>=10
0-1
Whether had anal sex between the pair
Yes
No
Participant in the bottom
when had anal sex between the pair
Yes
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Unadjusted Odds Ratio P
(95%CI)
0.031
8.40 (2.57-27.46)
Reference
0.406
1.02 (0.97-1.08)
Reference
0.307
1.00 (0.97-1.04)
0.98 (0.95-1.01)
Reference
0.654
1.00 (0.99-1.01)
Reference
0.892
1.00 (0.97-1.02)
Reference
0.705
0.99 (0.95-1.02)
1.00 (0.96-1.03)
Reference
0.705
0.99 (0.95-1.02)
1.00 (0.96-1.03)
Reference
0.522
1.00 (0.98-1.03)
0.98 (0.96-1.01)
Reference
0.374
1.01 (0.99-1.04)
Reference
0.396
1.00 (0.99-1.01)
1.01 (0.99-1.02)
Reference
0.712
1.00 (0.99-1.02)
Reference
0.578
1.00 (0.99-1.02)

Covariates
No
Consistent condom use between the pair
Yes
Unknown
No
Whether use drugs before sex
between the pair
Yes
No
Attended group sex together
Yes
No
Homophily of participants and sexual partners
Age homophily
Participant ≤ Sexual partner
Participant > Sexual partner
Race homophily
(participant / sexual partner)
Black / Black
Black / non-Black
non-Black / Black
non-Black / non-Black
HIV infection status homophily
(participant / sexual partner)

Unadjusted Odds Ratio P
(95%CI)
Reference
0.384
1.01 (0.97-1.04)
0.99 (0.97-1.02)
Reference
0.192
1.02 (0.99-1.06)
Reference
0.436
2.13 (0.55-8.26)
Reference
0.117
0.96 (0.93-1.00)
Reference
0.952
1.26 (0.37-4.28)
1.23 (0.36-4.17)
0.99 (0.91-1.08)
Reference
NA*

*GEE model cannot estimate parameters due to small cell numbers.
a Other: syphilis mono-infection, HIV mono-infection, and neither syphilis nor HIV infection
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Table 4 Results of multivariable GEE model of the dyadic data of participant and
sexual partners pairs in Houston, TX (N=983)
Parameter

Adjusted Odds Ratio
(95%CI)

Age homophily
Participant ≤ sexual partner

0.76 (0.55-1.05)

Participant > sexual partner

Reference

HIV infection
Yes

2.76 (0.55-13.89)

No

Reference

Participant’s syphilis/HIV infection status
Syphilis/HIV co-infection

4.45 (1.05-18.76)

Other a

Reference

Participant and his sexual partner used drugs before sex
Yes

1.21 (0.85-1.71)

No

Reference

a Other: syphilis mono-infection, HIV mono-infection, and neither syphilis nor HIV
infection
Funding
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CONCLUSION

In these three studies, we have provided epidemiological evidence that supports
findings from previous studies that MSM who use drugs but not injection drugs
(NIDU MSM) were at risk for HCV infection. (1) Overall HCV prevalence in NIDU
MSM was higher than the rest of general population; (2) NIDU MSM >=42 years old
had a higher risk of HCV infection than NIDU MSM <42 years old; (3) NIDU
MSM >=42 years old who used >6 drugs were associated with increased probability
of HCV infection among all NIDU MSM; (4) Among NIDU YMSM, syphilis monoinfection, HIV mono-infection, and syphilis/HIV co-infection were associated with
increased risk of HCV infection.

The strength of our studies was the use of NIDU MSM data from two projects (DASH
and YMAP) funded by NIDA and NIH. NIDU MSM in DASH project with a median
age of 42 years, represented NIDU MSM of older generation, while NIDU MSM in
YMAP project with a median age of 25 years represented NIDU MSM of younger
generation. By comparing findings from these two data sources, we could compare
characteristic that associated with HCV infection in different generations to some
extent. We found that syphilis infection was associated with HCV infection in
younger generation but not in older generation. One possible reason was that
syphilis status was self-reported in DASH project, which may underestimate the
effect of syphilis infection on HCV transmission. Another possible reason was that
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syphilis infection was increasing fast in recent years, especially in young people,
which reflected the increasing evidence of sexually transmitted HCV in recent years.

The strength of our studies also included the use of two statistical approaches which
were latent class analysis and dyadic data analysis to analyze NIDU MSM. Latent
class analysis made it possible to analyze all information on drug use types in one
analysis, by subgrouping the individuals using similar drug types. Dyadic data
analysis incorporated characteristics of sexual partnership into the analysis.
Although we could not identify statistically significant characteristics of sexual
partnership related to HCV infection, it was the first study to use this approach for
HCV study targeting NIDU MSM to the best of our knowledge.

Our studies had some limitations, particularly those pertaining to sample size issue.
Because our target population was hard-to-reach population, we could not obtain
large sample size to guarantee enough statistical power. Also, the question related
to sexual behavior and drug use behavior may also be underreported, which may
lead to underestimating the effect of sexual behavior and drug use behavior on HCV
transmission.

Further study is warranted specifically among NIDU MSM, with a larger sample size,
to more fully examine risk factors related to HCV infection, with efforts to obtain HCV
infection status for both the participant and the sexual partner and information on
sharing equipment of non-injection drugs.
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Finally, we conclude that NIDU MSM >=42 years old with multiple drug use are at
risk of HCV infection; YMSM with HIV mono-infection, syphilis mono-infection, and
HIV/syphilis co-infection are at risk of HCV infection. Health education should be
promoted in these subgroups to enhance the awareness of HCV infection and
increase HCV testing rates. In addition, treatment in HIV and/or syphilis infected
YMSM may help reduce the disease burden of HCV directly. Also, programs
targeting on increasing syphilis and HIV testing and treatment among YMSM may
potentially reduce the transmission HCV in YMSM.
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APPENDICES
Appendix A: Screening questionnaire for DASH project
SCREENER

I.D.#_______________

Date: ____________

READ: This is just a screener questionnaire. The information obtained here is voluntary.
You will not receive any money for answering these questions. This information will be
entered into our computer which will decide if you qualify. Only if you qualify and finish the
study will you receive any money.
ASK ALL OF THESE QUESTIONS:
1. Race? _______________

Montrose

Shotwell

2. Male or Female

3. How old are you?

_________
4. What is your birthday? ________-_________-________
5. Do you currently have a permanent address?
Y

N
What is your address?________________________________Phone

#________________
Are you currently living in a shelter?
street?

Y

Y

N

Are you currently living on the

N

6. Have you used crack cocaine in the last 48 hours?

Y

N

# of

Y

N

# of

Y

N

# of

Y

N

# of

Y

N

# of times

Y N

# of times

times_______
7. Have you used crack cocaine in the last 7 days?
times_______
8. Have you used powder cocaine in the last 48 hours?
times_______
9. Have you used powder cocaine in the last 7 days?
times_______
10. Have you used heroin in the last 48 hrs?
_______
11. Have you used heroin in the last 7 days?
_______
12. Have you used marijuana in the last 48 hours?
times_______
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Y

N

# of

13. Have you used marijuana in the last 7 days?

Y

N

# of

Y N

# of

Y N

# of

Y

N

# of

Y

N

# of

times_______
14. Have you used meth (crystal) in the last 48 hrs?
times_______
15. Have you used meth (crystal) in the last 7 days?
times_______
16. Have you used alcohol in the last 48 hours?
times_______
17. Have you used alcohol in the last 7 days?
times_______
18. Have you ever injected drugs?

Y

N

# of times_______ in the past 30 days

Have you injected drugs in the last 7 days?

Y

N

Have you ever shared needles or works while injecting any drug? Y

N

# of times

past 30 days_____
How many years have you injected drugs? _____________
19. Do you smoke cigarettes? Y

N

If yes, how many in a day?

________
20. Do you have a main sex partner? Y N
21. Have you had sex with a casual sex partner in the last week? Y N
22. Have you had sex with a new sex partner in the last week?

Y N

23. Have you had vaginal/oral/anal sex in the last 48 hours? List # of times for each
# vag_________ # oral___________ # anal___________
How many men?_________

How many women?_______

24. Have you had vaginal/oral/anal sex in the last 7 days?

List # of times for each

# vag_________ # oral___________ # anal___________
How many men?_________

How many women?_______

25. How many times have you had vaginal or anal sex in the last 30 days? ______
How many men?_________

How many women?_______

26. Do you use condoms with all your partners?

Y

N

27. Of the people you had sex with, what percentage of them did you use a condom with?
None___ Quarter___ Half___ Three-quarters___ All___
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28. Do you trade sex for money/drugs?

Y

N

If No, skip to Question 33

29. Have you traded sex for money/drugs in the last 48 hrs? Y N

# of

times_______
How many men?_________

How many women?_______

30. Have you traded sex for money/drugs in the last week?

Y N

# of

times_______
How many men?_________

How many women?_______

Have you traded sex for money in the last 30 days?

Y N

# of

times_______
How many men?_________

How many women?_______

Have you traded sex for drugs in the last 30 days?

Y N

# of

times_______
How many men?_________

How many women?_______

31. What part of town do you normally work in? ______________________________
32. Do you work on the streets? Y

N

33. Do you consider yourself: Gay____ Straight____ Bisexual_____
34. Have you ever been tested for HIV?

Y

N

Status? Positive

Negative

Don’t

Know
If HIV+, are you currently on meds? Y
Y

N Are you currently under a physician’s care?

N

If a vaccine was available for HIV, would you be willing to be vaccinated?
Y N
35. In your lifetime, have you ever been tested for a sexually transmitted disease?
Y

N

If yes, what types:
Syphilis___ Gonorrhea___ Chlamydia___ Genital Herpes___ Genital warts___
Other______
In your lifetime, have you ever been diagnosed or treated with a sexually transmitted
disease? Y

N

If yes, what types:
Syphilis___ Gonorrhea___ Chlamydia___ Genital Herpes___ Genital warts___
Other______
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If you were not treated, what was the reason?
__________________________________________
36. Have you been vaccinated against hepatitis B?

Y

N

If not, are you willing to be vaccinated against hepatitis B? Y
37. Have you ever been in drug treatment?

Y

N

N

# of times_______

38. Have you ever received a transfusion with blood or blood products (including clotting
factors)?

Y

N

If yes, what was the year of your first

transfusion? ________
39. Have you ever been employed as a medical, dental, public safety or other health care
worker involved with human blood contact?

Y

N

What was your job description?_________________________________________
What was your degree of blood contact?

Frequent_____

40. Have you ever been in prison or jail for more than 24 hours?

Infrequent_____
Y

N

Interviewer read: I am going to ask you about a place where you may have smoked
crack in the last 30 days. One of the places I am going to ask you about is a place
where someone pays money or gives the owner some crack to smoke at his/her
place. We call this kind of place a crack house. What do you call such a place?
_____
[Interviewer: Record responses other than a ‘crack house.’ If the respondent calls a
place where someone pays money or gives the owner some crack to smoke at his/her
place by a different name, use that name in referring to a ‘crack house.’]
41. In the past 30 days, how many times did you smoke crack in each of the following
places?
At your home
At a friend’s home
At an acquaintance’s (someone you did not know well) home
In a crack house
In a bar
In a public place, like a park, alley, public restroom

_____
_____
_____
_____
_____
_____
Times

If the response to smoking in a crack house was 0, skip to item ____. If the response
to smoking in a crack house is 1 or more times, ask:
41a. When you smoked in a crack house, what was the usual number of people present
during the times you were smoking?
1 other person _____
2 to 3 other people _____
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4 to 5 other people _____
5 to 10 other people _____
More than 10 other people _____
If the response to 41a is 1 other person, skip to 41c. If the response is 2 or more
people, ask:
41b. How many times did you smoke in a crack house when two or more persons were
present?
____
Times
41c. Of the ____ times you smoked in a crack house, how many times did you pay
money to smoke there?
____
Times
41d. Of the ____ times you smoked in a crack house, how many times did you give the
owner crack to smoke there?
____
Times
41e. Of the ____ times you smoked in a crack house, how many times did you have sex
while you were there?
_____
Times
42. How many people do you know have tuberculosis right now?
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_____
Number

If the response to 42 is 0, skip to 42. If two or more, go to 42b. If the response is 1
ask:
42a. What is the relationship of this person to you?
Relative _____
Sex partner _____
Someone you hang out with currently _____
Someone you work with _____
Someone that you were with in jail _____
Someone you were in a shelter with _____
Y/N
42b. How many people you know who have tuberculosis are related to you in the
following ways?
Relative _____
Sex partner _____
Someone you hang out with currently _____
Someone you work with _____
Someone that you were with in jail _____
Someone you were in a shelter with _____
number
42c. How many people do you know who are taking medication for tuberculosis right
now?
_____
Number
If the response to 42c is 0, skip to 43. If two or more, go to 42e. If the response is 1
ask:
42d. What is the relationship of this person to you?
Relative _____
Sex partner _____
Someone you hang out with currently _____
Someone you work with _____
Someone that you were with in jail _____
Someone you were in a shelter with _____
Y/N
42e. How many people you know taking medications for tuberculosis are related to you
in the following ways?
Relative _____
Sex partner _____
Someone you hang out with currently _____
Someone you work with _____
Someone that you were with in jail _____
Someone you were in a shelter with _____
number
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43. Who referred you to our study? ________________________________________

COMBO TEST RESULTS

HIV

HBsAG

HCV

Positive
Negative
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